Skip to content
2000
Volume 32, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Essential hypertension is a major cardiovascular pathology globally, with an estimated prevalence of approximately 33%, and it is a significant contributor to both mortality and adverse cardiovascular events. Finding early prognostic markers in such individuals could, thus, provide enhanced risk stratification and identification of patients with higher odds of target-organ damage or adverse events. Microalbuminuria is defined as an abnormal excretion of albumin in urine, is well associated with vascular disease, endothelial dysfunction, and low-grade inflammation, and is a marker of subclinical renal damage. Through the years, microalbuminuria at baseline has been well correlated with increasing blood pressure levels and blood pressure patterns, , non-dipping phenotype. At the same time, its presence in hypertensive individuals indicated increased rates of mortality, renal disease progression, and major adverse cardiovascular outcomes, including stroke and myocardial infarction. Thus, microalbuminuria can provide a prognostic marker of future adverse events in hypertensive individuals. Interestingly, standard antihypertensive pharmacotherapy and newer drugs have shown regression of microalbuminuria extent and renoprotection in both diabetic as well as hypertensive individuals, implying that early therapy could decrease the rate of disease progression and limit target-organ damage. Thus, the aim of this review is to analyze the available studies documenting the predictive role of microalbuminuria for both mortality, target-organ damage, and adverse events, as well as describe the impact of pharmacotherapy in the presence and extent of subclinical renal damage, as shown by the levels of this marker.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673348953250310044927
2025-03-25
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673348953250310044927
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FerrariA.J. SantomauroD.F. AaliA. AbateY.H. AbbafatiC. AbbastabarH. Abd ElHafeezS. AbdelmassehM. Abd-ElsalamS. AbdollahiA. AbdullahiA. AbegazK.H. ZuñigaR.A.A. AboagyeR.G. AbolhassaniH. AbreuL.G. AbualruzH. Abu-GharbiehE. Abu-RmeilehN.M.E. AckermanI.N. AddoI.Y. AddoloratoG. AdebiyiA.O. AdepojuA.V. AdewuyiH.O. AfyouniS. AfzalS. AfzalS. AgodiA. AhmadA. AhmadD. AhmadF. AhmadS. AhmedA. AhmedL.A. AhmedM.B. AjamiM. AkinosoglouK. AkkaifM.A. Al HasanS.M. AlalalmehS.O. Al-AlyZ. AlbashtawyM. AldridgeR.W. AlemuM.D. AlemuY.M. AleneK.A. Al-GheethiA.A.S. AlharrasiM. AlhassanR.K. AliM.U. AliR. AliS.S.S. AlifS.M. AljunidS.M. Al-MarwaniS. AlmazanJ.U. AlomariM.A. Al-OmariB. AltaanyZ. Alvis-GuzmanN. Alvis-ZakzukN.J. AlwafiH. Al-WardatM.S. Al-WorafiY.M. AlyS. AlzoubiK.H. AmareA.T. AmegborP.M. AmeyawE.K. AminT.T. AmindarolzarbiA. AmiriS. AmugsiD.A. AncuceanuR. AnderliniD. AndersonD.B. AndradeP.P. AndreiC.L. AnsariH. AntonyC.M. AnwarS. AnwarS.L. AnwerR. AnyanwuP.E. ArabJ.P. ArablooJ. ArafatM. ArakiD.T. AravkinA.Y. ArkewM. ArmocidaB. ArndtM.B. AroojM. ArtamonovA.A. ArulebaR.T. ArumugamA. AshbaughC. AshemoM.Y. AshrafM. AsikaM.O. AskariE. Astell-BurtT. AthariS.S. AtorkeyP. AtoutM.M.W. AtreyaA. AujayebA. AusloosM. AvanA. AwotidebeA.W. Awuviry-NewtonK. Ayala QuintanillaB.P. Ayuso-MateosJ.L. AzadnajafabadS. AzevedoR.M.S. BabuA.S. BadarM. BadiyeA.D. BaghdadiS. BagheriN. BahS. BaiR. BakerJ.L. BakkannavarS.M. BakoA.T. BalakrishnanS. BamK. BanikP.C. BarchittaM. BardhanM. BardidehE. Barker-ColloS.L. BarqawiH.J. BarrowA. BarteitS. BaruaL. Bashiri AliabadiS. BasiruA. BasuS. BasuS. BathiniP.P. BatraK. BauneB.T. BayileyegnN.S. BehnamB. BehnoushA.H. BeiranvandM. Bejarano RamirezD.F. BellM.L. BelloO.O. BeloukasA. BensenorI.M. BerezvaiZ. BernabeE. BernsteinR.S. BettencourtP.J.G. BhagavathulaA.S. BhalaN. BhandariD. BhargavaA. BhaskarS. BhatV. BhattiG.K. BhattiJ.S. BhattiM.S. BhattiR. BhuttaZ.A. BikbovB. BishaiJ.D. BisignanoC. BitraV.R. BjørgeT. BodolicaV. BodunrinA.O. BogaleE.K. Bonakdar HashemiM. BonnyA. Bora BasaraB. BorhanyH. BoxeC. BradyO.J. BragazziN.L. BraithwaiteD. BrantL.C. BrauerM. BreitnerS. BrennerH. BrownJ. BrughaT. BulamuN.B. BuonsensoD. BurkartK. BurnsR.A. BusseR. BustanjiY. ButtZ.A. ByunJ. Caetano dos SantosF.L. CalinaD. CámeraL.A. Campos-NonatoI.R. CaoC. CapodiciA. CarrS. CarrerasG. CarugnoA. CarvalhoM. Castaldelli-MaiaJ.M. Castañeda-OrjuelaC.A. CastelpietraG. CatapanoA.L. CattaruzzaM.S. CayeA. CegolonL. CembranelF. CenderadewiM. CerinE. ChakrabortyP.A. ChanJ.S.K. ChanR.N.C. ChandikaR.M. ChandrasekarE.K. CharalampousP. ChattuV.K. Chatzimavridou-GrigoriadouV. ChenA.W. ChenA-T. ChenC.S. ChenH. ChenN.M. ChengE.T.W. Chimed-OchirO. ChimoriyaR. ChingP.R. ChoW.C.S. ChoiS. ChongB. ChongY.Y. ChoudhariS.G. ChowdhuryR. ChristensenS.W.M.P. ChuD-T. ChukwuI.S. ChungE. ChungE. ChutiyamiM. ClaassensM.M. CogenR.M. ColumbusA. CondeJ. CortesiP.A. CousinE. CriquiM.H. Cruz-MartinsN. DadrasO. DaiS. DaiX. DaiZ. DalabaM.A. DamianiG. DasJ.K. DasS. DashtiM. Dávila-CervantesC.A. DavletovK. De LeoD. DebeleA.T. DebopadhayaS. DeCleeneN.K. DeebaF. DegenhardtL. Del Bo’C. Delgado-EncisoI. DemetriadesA.K. Denova-GutiérrezE. DervenisN. DesaiH.D. DesaiR. DeubaK. DhamaK. DharmaratneS.D. DhingraS. Dias da SilvaD. DiazD. DiazL.A. DiazM.J. DimaA. DingD.D. DiracM.A. DoT.H.P. do PradoC.B. DohareS. DominguezR-M.V. DongW. DongarwarD. D’OriaM. DorseyE.R. DoshmangirL. DowouR.K. DriscollT.R. DsouzaH.L. DsouzaV. DubeJ. DumithS.C. DuncanB.B. DuraesA.R. DuraisamyS. DurojaiyeO.C. DzianachP.A. DziedzicA.M. EboreimeE. EbrahimiA. EdinurH.A. EdvardssonD. EikemoT.A. EiniE. EkholuenetaleM. EkundayoT.C. El SayedI. El TantawiM. ElbaraziI. ElemamN.M. ElGoharyG.M.T. ElhadiM. ElmeligyO.A.A. ELNahasG. ElshaerM. ElsohabyI. Engelbert BainL. ErkhembayarR. EshratiB. EstepK. FabinN. FagbamigbeA.F. FalzoneL. FareedM. FarinhaC.S.S. FarisM.A.I.E.M. FaroA. FarrokhiP. FatehizadehA. FaukN.K. FeiginV.L. FengX. FereshtehnejadS-M. FerozeA.H. FerreiraN. FerreiraP.H. FischerF. FlavelJ. FloodD. FlorL.S. FoigtN.A. FolayanM.O. ForceL.M. FortunaD. FoschiM. FranklinR.C. FreitasA. FukumotoT. FurtadoJ.M. GaalP.A. GadanyaM.A. GaidhaneA.M. GaihreS. GalaliY. GanbatM. GandhiA.P. GanesanB. GanieM.A. GaniyaniM.A. GardnerW.M. GebiT.G. GebregergisM.W. GebrehiwotM. GebremariamT.B.B. GebremeskelT.G. GelaY.Y. GeorgescuS.R. Getachew ObsaA. GethingP.W. GetieM. GhadiriK. GhadirianF. GhailanK.Y. GhajarA. GhasemiM.R. Ghasempour DabaghiG. GhasemzadehA. GhazyR.M. GholamrezanezhadA. GhorbaniM. GhotbiE. GibsonR.M. GillT.K. GinindzaT.G. GirmayA. GlasbeyJ.C. GöbölösL. GodinhoM.A. GoharinezhadS. GoldustM. GolechhaM. GoleijP. GonaP.N. GoriniG. GoulartA.C. GradaA. GrivnaM. GuanS-Y. GuarducciG. GubariM.I.M. GudetaM.D. GuhaA. GuicciardiS. GulatiS. GulisashviliD. GunawardaneD.A. GuoC. GuptaA.K. GuptaB. GuptaI. GuptaM. GuptaR. GuptaV.B. GuptaV.K. GuptaV.K. GutiérrezR.A. HabibzadehF. HabibzadehP. HaddadiR. HadiN.R. HaepN. Hafezi-NejadN. HafizA. HaginsH. HalboubE.S. HalimiA. HallerS. HalwaniR. HamiltonE.B. HankeyG.J. HannanM.A. HaqueM.N. HarapanH. HaroJ.M. HartvigsenJ. HasaballahA.I. HasanI. HasanianM. HasnainM.S. HassanA. HauboldJ. HavmoellerR.J. HayS.I. HayatK. HebertJ.J. HegaziO.E. HeidariG. HelferB. HemmatiM. HendrieD. HensonC.A. HezamK. HiraikeY. HoanN.Q. HollaR. HonJ. HossainM.M. HosseinzadehH. HosseinzadehM. HostiucM. HostiucS. HsuJ.M. HuangJ. HugoF.N. HushmandiK. HussainJ. HusseinN.R. HuynhC.K. HuynhH-H. HwangB-F. IannucciV.C. IhlerA.L. IkiromaA.I. IkutaK.S. IlesanmiO.S. IlicI.M. IlicM.D. ImamM.T. ImmuranaM. IrhamL.M. IslamM.R. IslamS.M.S. IslamiF. IsmailF. IsmailN.E. IsolaG. IwagamiM. IwuC.C.D. IyerM. JaafariJ. JacobsenK.H. Jadidi-NiaraghF. JafariniaM. JaggiK. JahankhaniK. JahanmehrN. JahramiH. JainA. JainN. JairounA.A. JaiswalA. JakovljevicM. JatauA.I. JavadovS. JavaheriT. JayapalS.K. JayaramS. JeeS.H. JeganathanJ. JeyakumarA. JhaA.K. JiangH. JinY. JonasJ.B. JooT. JosephA. JosephN. JoshuaC.E. JozwiakJ.J. JürissonM. KV. KaambwaB. KabirA. KabirZ. KadashettiV. KalaniR. KalankeshL.R. KaliyadanF. KalraS. KamenovK. KamyariN. KanagasabaiT. KandelH. KanmanthareddyA.R. KanmodiK.K. KantarR.S. KarayeI.M. KarimA. KarimiS.E. KarimiY. KasraeiH. KasselM.B. KauppilaJ.H. KawakamiN. KayodeG.A. KazemiF. KazemianS. Keikavoosi-AraniL. KellerC. KempenJ.H. KerrJ.A. KeshtkarK. Kesse-GuyotE. KeykhaeiM. KhajuriaH. KhalajiA. KhalidA. KhalidN. KhalilianA. KhamesipourF. KhanA. KhanI. KhanM. KhanM.A.B. KhanmohammadiS. KhatabK. KhatamiF. KhatatbehM.M. KhaterA.M. Khayat KashaniH.R. KhidriF.F. KhodadoustE. KhormaliM. KhorramiZ. KifleZ.D. KimM.S. KimokotiR.W. KisaA. KisaS. KnudsenA.K.S. KocarnikJ.M. KochharS. KohH.Y. KolahiA-A. KompaniF. KorenG. KorzhO. KosenS. Koulmane LaxminarayanaS.L. KrishanK. KrishnaV. KrishnamoorthyV. Kuate DefoB. KuddusM.A. KuddusM. KuitunenI. KulkarniV. KumarM. KumarN. KumarR. KurmiO.P. KusumaD. KyuH.H. La VecchiaC. LaceyB. LadanM.A. LaflammeL. LafranconiA. LahariyaC. LaiD.T.C. LalD.K. LallooR. LallukkaT. LámJ. LanQ. LanT. LandiresI. LanfranchiF. LangguthB. Laplante-LévesqueA. LarijaniB. LarssonA.O. LasradoS. LauriolaP. LeH-H. LeL.K.D. LeN.H.H. LeT.D.T. LeasherJ.L. LeddaC. LeeM. LeeP.H. LeeS. LeeS.W. LeeW-C. LeeY.H. LeGrandK.E. LenziJ. LeongE. LeungJ. LiM-C. LiW. LiX. LiY. LiY. LimL-L. LimS.S. LindstromM. LinnS. LiuG. LiuR. LiuS. LiuW. LiuX. LiuX. LlanajE. LoC-H. López-BuenoR. LorecheA.M. LorenzoviciL. LozanoR. LubindaJ. LucchettiG. LuneviciusR. LuskJ.B. lv MaZ.F. MachairasN. Madureira-CarvalhoÁ.M. Magaña GómezJ.A. MaghazachiA.A. MaharjanP. MahashaP.W. MaheriM. MahjoubS. MahmoudM.A. MahmoudiE. MajeedA. MakrisK.C. Malakan RadE. MalhotraK. MalikA.A. MalikI. MaltaD.C. ManlaY. MansourA. MansouriP. MansourniaM.A. Mantilla HerreraA.M. MantovaniL.G. ManuE. MaratebH.R. MardiP. MartinezG. Martinez-PiedraR. MartiniD. Martins-MeloF.R. MartorellM. MarxW. MaryamS. MarzoR.R. MathangasingheY. MathiesonS. MathioudakisA.G. MattumpuramJ. MaugeriA. MayeliM. MazidiM. MazzottiA. McGrathJ.J. McKeeM. McKowenA.L.W. McPhailM.A. Mehrabani-ZeinabadK. Mehrabi NasabE. Mekene MetoT. MendozaW. MenezesR.G. MensahG.A. MentisA-F.A. MeoS.A. MeresaH.A. MeretojaA. MeretojaT.J. MershaA.M. MestrovicT. MettanandaK.C.D. MettanandaS. MichalekI.M. MillerP.A. MillerT.R. MillsE.J. MinhL.H.N. MirijelloA. MirrakhimovE.M. MirutseM.K. Mirza-Aghazadeh-AttariM. MirzaeiM. MirzaeiR. MisganawA. MishraA.K. MitchellP.B. MittalC. MoazenB. MobergM.E. MohamedJ. MohamedM.F.H. MohamedN.S. MohammadiE. MohammadiS. MohammedH. MohammedS. MohammedS. MohrR.M. MokdadA.H. MolinaroS. MomtazmaneshS. MonastaL. MondelloS. Moodi GhalibafA.A. MoradiM. MoradiY. Moradi-LakehM. MoragaP. MorawskaL. MoreiraR.S. MorovatdarN. MorrisonS.D. MorzeJ. MosapourA. MosserJ.F. MossialosE. MotappaR. MouginV. MouodiS. MrejenM. MsherghiA. MubarikS. MuellerU.O. MulitaF. MunjalK. Murillo-ZamoraE. MurlimanjuB.V. MustafaG. MuthuS. MuzaffarM. MyungW. NagarajanA.J. NaghaviP. NaikG.R. NainuF. NairS. NajmuldeenH.H.R. NangiaV. NaqviA.A. NarayanaA.I. NargusS. NascimentoG.G. NashwanA.J. NasrollahizadehA. NasrollahizadehA. NattoZ.S. NayakB.P. NayakV.C. NduagubaS.O. NegashH. NegoiI. NegoiR.I. NejadghaderiS.A. NesbitO.D. NetsereH.B. NgM. Nguefack-TsagueG. NgunjiriJ.W. NguyenD.H. NguyenH.Q. NiaziR.K. NikolouzakisT.K. NikoobarA. NikoomaneshF. NikpoorA.R. NnajiC.A. NnyanziL.A. NomanE.A. NomuraS. NorrvingB. Nri-EzediC.A. NtaiosG. NtsekheM. NurrikaD. NzoputamC.I. NzoputamO.J. OanceaB. OdetokunI.A. O’DonnellM.J. OguntadeA.S. OgutaJ.O. Okati-AliabadH. OkekeS.R. OkekunleA.P. OkonjiO.C. OlagunjuA.T. OlasupoO.O. OlatubiM.I. OliveiraG.M.M. OlufadewaI.I. OlusanyaB.O. OlusanyaJ.O. OmarH.A. OmerG.L. OmonisiA.E.E. OnieS. OnwujekweO.E. OrdakM. OrishV.N. Ortega-AltamiranoD.V. OrtizA. Ortiz-BrizuelaE. OsmanW.M.S. OstroffS.M. OsuagwuU.L. OtoiuA. OtstavnovN. OtstavnovS.S. OuyahiaA. OuyangG. OwolabiM.O. P AM.P. Padron-MonederoA. PadubidriJ.R. PaliczT. PalladinoC. PanF. Pandi-PerumalS.R. PangaribuanH.U. PanosG.D. PanosL.D. Pantea StoianA.M. PardhanS. ParikhR.R. PashaeiA. PasovicM. PasseraR. PatelJ. PatelS.K. PatilS. PatouliasD. PatthipatiV.S. PawarS. Pazoki ToroudiH. PeaseS.A. PedenA.E. PedersiniP. PengM. PensatoU. PepitoV.C.F. PeprahE.K. PeprahP. PerdigãoJ. PereiraM.O. PerianayagamA. PericoN. PesudovsK. Petermann-RochaF.E. PetriW.A. PhamH.T. PhilipA.K. PhillipsM.R. PigeoletM. PigottD.M. PillayJ.D. PirachaZ.Z. PirouzpanahS. PlassD. PlotnikovE. PoddigheD. PolinderS. PostmaM.J. PourtaheriN. PradaS.I. PradhanP.M.S. PrakashV. PrasadM. PratesE.J.S. PriscillaT. PritchettN. PuriP. PuvvulaJ. QasimN.H. QatteaI. QaziA.S. QianG. Rabiee RadM. RadhakrishnanR.A. RadhakrishnanV. Raeisi ShahrakiH. RaffertyQ. RaggiA. RaghavP.R. RahimM.J. RahmanM.M. RahmanM.H.U. RahmanM. RahmanM.A. RahmaniS. RahmanianM. RahmawatyS. RajaaS. RamadanM.M. RamasamyS.K. RamasubramaniP. RamazanuS. RanaK. RanabhatC.L. RancicN. RaneA. RaoC.R. RaoK. RaoM. RaoS.J. RashidiM-M. Rathnaiah BabuG. RauniyarS.K. RawafD.L. RawafS. RazoC. ReddyM.M.R.K. RedwanE.M.M. ReifelsL. ReinerR.C.Jr RemuzziG. RenzahoA.M.N. ReshmiB. ReyesL.F. RezaeiN. RezaeiN. RezaeiN. Rezaei HachesuP. RezaeianM. RickardJ. RodriguesC.F. RodriguezJ.A.B. RoeverL. RonfaniL. RoshandelG. RotimiK. RoutH.S. RoyB. RoyN. RoyP. RubagottiE. S NC. SaadA.M.A. Saber-AyadM.M. SabourS. SaccoS. SachdevP.S. SaddikB. SaddlerA. SadeeB.A. SadeghiE. SadeghiM. SaebM.R. SaeedU. SafiS.Z. SagarR. SagoeD. SaifZ. SajidM.R. SakshaugJ.W. SalamN. SalamiA.A. SalaroliL.B. SalehM.A. SalemM.R. SalemM.Z.Y. SallamM. SamadzadehS. SamargandyS. SamodraY.L. SamyA.M. SanabriaJ. SannaF. SantosI.S. Santric-MilicevicM.M. SarasmitaM.A. SarikhaniY. Sarmiento-SuárezR. SarodeG.S. SarodeS.C. SarveazadA. SathianB. SathyanarayanA. SatpathyM. SawhneyM. ScarmeasN. SchaarschmidtB.M. SchmidtM.I. SchneiderI.J.C. SchumacherA.E. SchwebelD.C. SchwendickeF. SedighiM. SenapatiS. SenthilkumaranS. SepanlouS.G. SethiY. SetoguchiS. SeylaniA. ShadidJ. ShafieM. ShahH. ShahN.S. ShahP.A. ShahbandiA. ShahidS. ShahidW. ShahwanM.J. ShaikhM.A. ShakeriA. ShalashA.S. ShamS. ShamimM.A. ShamshirgaranM.A. ShamsiM.A. ShanawazM. ShankarA. ShannawazM. SharathM. SharifanA. Sharifi-RadJ. SharmaM. SharmaR. SharmaS. SharmaU. SharmaV. ShastryR.P. ShavandiA. ShayanA.M. ShayanM. ShehabeldineA.M.E. ShettyP.H. ShibuyaK. ShifaJ.E. ShiferawD. ShiferawW.S. ShigematsuM. ShiriR. ShitayeN.A. ShittuA. ShivakumarK.M. ShivarovV. Shokati EshkikiZ. ShoolS. ShresthaS. ShuvalK. SibhatM.M. SiddigE.E. SigfusdottirI.D. SilvaD.A.S. SilvaJ.P. SilvaL.M.L.R. SilvaS. SimpsonC.R. SingalA. SinghA. SinghB.B. SinghH. SinghJ.A. SinghM. SinghP. SkouS.T. SleetD.A. SlepakE.L.N. SolankiR. SolimanS.S.M. SongS. SongY. SorensenR.J.D. SorianoJ.B. SoyiriI.N. SpartalisM. SreeramareddyC.T. StarkB.A. StarodubovaA.V. SteinC. SteinD.J. SteinerC. SteinerT.J. SteinmetzJ.D. SteiropoulosP. StockfeltL. StokesM.A. SubediN.S. SubramaniyanV. SuemotoC.K. SulemanM. Suliankatchi AbdulkaderR. SultanaA. SundströmJ. SwainC.K. SzarpakL. Tabaee DamavandiP. Tabarés-SeisdedosR. Tabatabaei MalazyO. TabatabaeizadehS-A. TabatabaiS. TabcheC. TabishM. TadakamadlaS.K. Taheri AbkenarY. Taheri SoodejaniM. TaherkhaniA. TaibaJ. TalaatI.M. TalukderA. TampaM. TamuziJ.L. TanK-K. TandukarS. TangH. Tavakoli OliaeeR. TavangarS.M. TeimooriM. TemsahM-H. TeramotoM. ThangarajuP. ThankappanK.R. ThaparR. ThayakaranR. ThirunavukkarasuS. ThomasN. ThomasN.K. ThumC.C.C. TichopadA. TicoaluJ.H.V. TillawiT. TiruyeT.Y. Tobe-GaiR. TonelliM. Topor-MadryR. TorreA.E. TouvierM. Tovani-PaloneM.R. TranJ.T. TranM.T.N. TranN.M. TranN-H. TricoD. TromansS.J. TruyenT.T.T.T. TsatsakisA. TsegayG.M. TsermpiniE.E. TumurkhuuM. TyrovolasS. UdohA. UmairM. UmakanthanS. UmarT.P. UndurragaE.A. UnimB. UnnikrishnanB. UnsworthC.A. UpadhyayE. UrsoD. UsmanJ.S. VahabiS.M. VaithinathanA.G. Van den EyndeJ. VargaO. VarmaR.P. VartP. VasankariT.J. VasicM. VaziriS. VellingiriB. VenketasubramanianN. VerouxM. VerrasG-I. VervoortD. VillafañeJ.H. ViolanteF.S. VlassovV. VollsetS.E. VolovatS.R. VongpradithA. WaheedY. WangC. WangF. WangN. WangS. WangY. WangY-P. WardP. WassieE.G. WeaverM.R. WeerakoonK.G. WeintraubR.G. WeissD.J. WeldemariamA.H. WellsK.M. WenY.F. WhisnantJ.L. WhitefordH.A. WiangkhamT. WickramasingheD.P. WickramasingheN.D. WilandikaA. WilkersonC. WilleitP. WimoA. WoldegebrealD.H. WolfA.W. WongY.J. WoolfA.D. WuC. WuF. WuX. WuZ. Wulf HansonS. XiaY. XiaoH. XuX. XuY.Y. YadavL. YadollahpourA. YaghoubiS. YamagishiK. YangL. YanoY. YaoY. YaribeygiH. YazdanpanahM.H. YeP. YehualashetS.S. YesufS.A. YezliS. YiğitA. YiğitV. YigzawZ.A. YismawY. YonD.K. YonemotoN. YounisM.Z. YuC. YuY. YusufH. ZahidM.H. ZakhamF. ZakiL. ZakiN. ZamanB.A. ZamoraN. ZandR. ZandiehG.G.Z. ZarH.J. ZarrintanA. ZastrozhinM.S. ZhangH. ZhangN. ZhangY. ZhaoH. ZhongC. ZhongP. ZhouJ. ZhuZ. ZiafatiM. ZielińskaM. ZimsenS.R.M. ZoladlM. ZumlaA. ZyoudS.H. VosT. MurrayC.J.L. GBD 2021 Diseases and Injuries Collaborators Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021.Lancet2024403104402133216110.1016/S0140‑6736(24)00757‑838642570
     [Google Scholar]
  2. HansenT.W. JeppesenJ. RasmussenS. IbsenH. Torp-PedersenC. Ambulatory blood pressure and mortality: A population-based study.Hypertension200545449950410.1161/01.HYP.0000160402.39597.3b15753229
     [Google Scholar]
  3. OparilS. AcelajadoM.C. BakrisG.L. BerlowitzD.R. CífkováR. DominiczakA.F. GrassiG. JordanJ. PoulterN.R. RodgersA. WheltonP.K. Hypertension.Nat. Rev. Dis. Primers2018411801410.1038/nrdp.2018.1429565029
     [Google Scholar]
  4. CareyR.M. MoranA.E. WheltonP.K. Treatment of hypertension.JAMA2022328181849186110.1001/jama.2022.1959036346411
     [Google Scholar]
  5. ManciaG. KreutzR. BrunströmM. BurnierM. GrassiG. JanuszewiczA. MuiesanM.L. TsioufisK. Agabiti-RoseiE. AlgharablyE.A.E. AziziM. BenetosA. BorghiC. HitijJ.B. CifkovaR. CocaA. CornelissenV. CruickshankJ.K. CunhaP.G. DanserA.H.J. PinhoR.M. DellesC. DominiczakA.F. DorobantuM. DoumasM. Fernández-AlfonsoM.S. HalimiJ.M. JáraiZ. JelakovićB. JordanJ. KuznetsovaT. LaurentS. LovicD. LurbeE. MahfoudF. ManolisA. MiglinasM. NarkiewiczK. NiiranenT. PalatiniP. ParatiG. PathakA. PersuA. PoloniaJ. RedonJ. SarafidisP. SchmiederR. SpronckB. StabouliS. StergiouG. TaddeiS. ThomopoulosC. TomaszewskiM. Van de BorneP. WannerC. WeberT. WilliamsB. ZhangZ.Y. KjeldsenS.E. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension.J. Hypertens.202341121874207110.1097/HJH.000000000000348037345492
     [Google Scholar]
  6. TotoR.D. Microalbuminuria: Definition, detection, and clinical significance.J. Clin. Hypertens. (Greenwich)20046s11Suppl. 32710.1111/j.1524‑6175.2004.4064.x15538104
     [Google Scholar]
  7. ShinJ.I. ChangA.R. GramsM.E. CoreshJ. BallewS.H. SurapaneniA. MatsushitaK. BiloH.J.G. CarreroJ.J. ChodickG. DarathaK.B. JassalS.K. NadkarniG.N. NelsonR.G. NowakC. StempniewiczN. SumidaK. TraynorJ.P. WoodwardM. SangY. GansevoortR.T. ChalmersJ. TuttleK. AlicicR. McPhersonS. JonesC. SinghG. GreenJ. KirchnerH.L. ShalevV. BottingerE.P. LoosR.J.F. EllisS.B. CuddebackJ. CieminsE. CarbonaraE. DunningS. KnowlerW.C. LookerH.C. KienekerL.M. BakkerS.J.L. HillegeH.L. van der HarstP. JassalS.K. BergstromJ. IxJ. KovesdyC.P. PotukuchiP. TrevisanM. ElinderC.G. WettermarkB. ÄrnlövJ. MarkP.B. ThomsonP.C. GeddesC.C. LandmanG.W.D. van HaterenK.J.J. KleefstraN. GutierrezO. KontaT. LeveyA.S. PolkinghorneK. SchäffnerE. ChenJ. SurapeneniA. CKD Prognosis Consortium Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium.Hypertension20217841042105210.1161/HYPERTENSIONAHA.121.1732334365812
     [Google Scholar]
  8. McEvoyJ.W. McCarthyC.P. BrunoR.M. BrouwersS. CanavanM.D. CeconiC. ChristodorescuR.M. DaskalopoulouS.S. FerroC.J. GerdtsE. HanssenH. HarrisJ. LauderL. McManusR.J. MolloyG.J. RahimiK. Regitz-ZagrosekV. RossiG.P. SandsetE.C. ScheenaertsB. StaessenJ.A. UchmanowiczI. VolterraniM. TouyzR.M. AbreuA. OlsenM.H. AmbrosettiM. AndroulakisE. BangL.E. BechJ.N. BorgerM.A. BoutouyrieP. BronzeL. BuccheriS. DalmauR. De Pablo ZarzosaM.C. DellesC. FiuzaM.M. GabulovaR. HaugenB.O. HeissC. IbanezB. JamesS. KapilV. KayikçiogluM. KøberL. KoskinasK.C. LocatiE.T. MacDonaldS. MihailidouA.S. MihaylovaB. MindhamR. MortensenM.B. NardaiS. NeubeckL. NielsenJ.C. NilssonP.M. PasquetA.A. PedroM.M. PrescottE. RakishevaA. RietzschelE. RoccaB. RosselloX. SchmidJ-P. ShantsilaE. SudanoI. TimóteoA.T. TsivgoulisG. UngarA. VaartjesI. VisserenF. VoellerH. VrintsC. WitkowskiA. ZennaroM-C. ZeppenfeldK. ShukaN. LaredjN. PavoN. MirzoyevU. van de BorneP. SokolovićŠ. PostadzhiyanA. SamardzicJ. AgathangelouP. WidimskyJ. OlsenM.H. El-KilanyW.M. PauklinP. LaukkanenJ.A. BoulestreauR. TsinamdzgvrishviliB. KintscherU. MarketouM. PállD. HrafnkelsdóttirÞ.J. DolanE. WolakT. BiloG. TundybayevaM.K. MirrakhimovE. TrusinskisK. KiwanG. MsalemO. BadarienėJ. BanuC-A. BalbiM.M. CarausA. BoskovicA. MouineN. VromenT. BosevskiM. MidtbøH.B. DoroszkoA. DoresH. BadilaE. BiniR. SimićD.V. FrasZ. MazónP. SpaakJ. BurkardT. BarakatE. AbdessalemS. GunesY. SirenkoY.M. BradyA.J.B. KhamidullaevaG.A. ESC Scientific Document Group 2024 ESC Guidelines for the management of elevated blood pressure and hypertension.Eur. Heart J.202445383912401810.1093/eurheartj/ehae17839210715
     [Google Scholar]
  9. ManciaG. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).J Hypertens.202341121874207110.1097/HJH.0000000000003480
     [Google Scholar]
  10. DimitriadisK. SchmiederR.E. IliakisP. NickelL. TsioufisK. WeilJ. Long-term efficacy and safety of renal denervation: An update from registries and randomised trials.Blood Press.2023321226666410.1080/08037051.2023.226666437804153
     [Google Scholar]
  11. TsioufisC. DimitriadisK. KasiakogiasA. KalosT. LiatakisI. KoutraE. NikolopoulouL. KordalisA. EllaR.O. LauE.O.Y. GrassiG. PapademetriouV. TousoulisD. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome.J. Hypertens.20173551100110810.1097/HJH.000000000000126228106665
     [Google Scholar]
  12. NawarK. MohammadA. JohnsE.J. AbdullaM.H. Renal denervation for atrial fibrillation: A comprehensive updated systematic review and meta-analysis.J. Hum. Hypertens.2022361088789710.1038/s41371‑022‑00658‑035094013
     [Google Scholar]
  13. DimitriadisK. IliakisP. PyrpyrisN. TatakisF. FragkoulisC. MantziarisV. PlaitisA. BenekiE. TsioufisP. HeringD. KolliasA. KonstantinidisD. TsioufisK. Renal denervation in heart failure treatment: Data for a self-fulfilling prophecy.J. Clin. Med.20241322665610.3390/jcm1322665639597800
     [Google Scholar]
  14. MigliaroS. PetroliniA. MarianiS. TomaiF. Impact of renal denervation on patients with coronary microvascular dysfunction: Study rationale and design.J. Cardiovasc. Med. (Hagerstown)202425537938510.2459/JCM.000000000000160938477865
     [Google Scholar]
  15. DesaiA.S. WebbD.J. TaubelJ. CaseyS. ChengY. RobbieG.J. FosterD. HuangS.A. RhyeeS. SweetserM.T. BakrisG.L. Zilebesiran, an RNA interference therapeutic agent for hypertension.N. Engl. J. Med.2023389322823810.1056/NEJMoa220839137467498
     [Google Scholar]
  16. GburekJ. KonopskaB. GołąbK. Renal handling of albumin—from early findings to current concepts.Int. J. Mol. Sci.20212211580910.3390/ijms2211580934071680
     [Google Scholar]
  17. GekleM. Renal tubule albumin transport.Annu. Rev. Physiol.200567157359410.1146/annurev.physiol.67.031103.15484515709971
     [Google Scholar]
  18. SinghA. SatchellS.C. Microalbuminuria: Causes and implications.Pediatr. Nephrol.201126111957196510.1007/s00467‑011‑1777‑121301888
     [Google Scholar]
  19. RuilopeL.M. AlcázarJ.M. RodicioJ.L. Renal consequences of arterial hypertension.J. Hypertens. Suppl.1992107S85S901291661
     [Google Scholar]
  20. CottoneS. CerasolaG. Microalbuminuria fractional clearance and early renal permselectivity changes in essential hypertension.Am. J. Nephrol.199212532632910.1159/0001684671489001
     [Google Scholar]
  21. RodicioJ.L. CampoC. RuilopeL.M. Microalbuminuria in essential hypertension.Kidney Int.199854S51S5410.1046/j.1523‑1755.1998.06813.x9839284
     [Google Scholar]
  22. TsioufisC. DimitriadisK. StefanadisC. KallikazarosI. The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: Focus on microalbuminuria.Hellenic J. Cardiol.200647636136517243508
     [Google Scholar]
  23. TsioufisC. DimitriadisK. TaxiarchouE. VasiliadouC. ChartzoulakisG. TousoulisD. ManolisA. StefanadisC. KallikazarosI. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects.Am. J. Hypertens.200619546246610.1016/j.amjhyper.2005.07.02616647614
     [Google Scholar]
  24. TsioufisC. DimitriadisK. AndrikouE. ThomopoulosC. TsiachrisD. StefanadiE. MihasC. MiliouA. PapademetriouV. StefanadisC. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: A cross-sectional study.Am. J. Kidney Dis.20105561050105910.1053/j.ajkd.2009.11.02420189274
     [Google Scholar]
  25. FerrarioC.M. StrawnW.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.Am. J. Cardiol.200698112112810.1016/j.amjcard.2006.01.05916784934
     [Google Scholar]
  26. ChenFQ. Levels of inflammatory cytokines in type 2 diabetes patients with different urinary albumin excretion rates and their correlation with clinical variables.J Diabetes Res.2013201313896910.1155/2013/138969
     [Google Scholar]
  27. WenY. CrowleyS.D. Renal effects of cytokines in hypertension.Curr. Opin. Nephrol. Hypertens.2018272707610.1097/MNH.000000000000038529140820
     [Google Scholar]
  28. UpadhyayA. LarsonM.G. GuoC.Y. VasanR.S. LipinskaI. O’DonnellC.J. KathiresanS. MeigsJ.B. KeaneyJ.F.Jr RongJ. BenjaminE.J. FoxC.S. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort.Nephrol. Dial. Transplant.201126392092610.1093/ndt/gfq47120682604
     [Google Scholar]
  29. GargJ.P. BakrisG.L. Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease.Vasc. Med.200271354310.1191/1358863x02vm412ra12083733
     [Google Scholar]
  30. GalloG. VolpeM. SavoiaC. Endothelial dysfunction in hypertension: Current concepts and clinical implications.Front. Med. (Lausanne)2022879895810.3389/fmed.2021.79895835127755
     [Google Scholar]
  31. TsioufisC. DimitriadisK. AntoniadisD. StefanadisC. KallikazarosI. Inter-Relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects.Am. J. Hypertens.200417547047610.1016/j.amjhyper.2004.02.00815110909
     [Google Scholar]
  32. OchodnickyP. HenningR.H. van DokkumR.P.E. de ZeeuwD. Microalbuminuria and endothelial dysfunction: Emerging targets for primary prevention of end-organ damage.J. Cardiovasc. Pharmacol.200647Suppl. 2S151S16210.1097/00005344‑200606001‑0000916794452
     [Google Scholar]
  33. Feldt-RasmussenB. Increased transcapillary escape rate of albumin in Type 1 (insulin-dependent) diabetic patients with microalbuminuria.Diabetologia198629528228610.1007/BF004520633522326
     [Google Scholar]
  34. NannipieriM. RlzzoL. RapuanoA. PiloA. PennoG. NavalesiR. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients.Diabetes Care19951811910.2337/diacare.18.1.17698029
     [Google Scholar]
  35. NannipieriM. PennoG. RizzoL. PucciL. BandinelliS. MatteiP. TaddeiS. SalvettiA. NavalesiR. Transcapillary escape rate of albumin in type II diabetic patients. The relationship with microalbuminuria and hypertension.Diabetes Care19972061019102610.2337/diacare.20.6.10199167118
     [Google Scholar]
  36. PedrinelliR. PennoG. Dell’OmoG. BandinelliS. GiorgiD. Di BelloV. NavalesiR. MarianiM. Microalbuminuria and transcapillary albumin leakage in essential hypertension.Hypertension199934349149510.1161/01.HYP.34.3.49110489399
     [Google Scholar]
  37. PedrinelliR. GiampietroO. CarmassiF. MelilloE. Dell’OmoG. CatapanoG. MatteucciE. TalaricoL. MoraleM. De NegriF. Microalbuminuria and endothelial dysfunction in essential hypertension.Lancet19943448914141810.1016/S0140‑6736(94)91047‑27912295
     [Google Scholar]
  38. BlannA.D. McCollumC.N. von Willebrand factor, endothelial cell damage and atherosclerosis.Eur. J. Vasc. Surg.199481101510.1016/S0950‑821X(05)80112‑48307205
     [Google Scholar]
  39. KarioK. MatsuoT. KobayashiH. MatsuoM. SakataT. MiyataT. ShimadaK. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria.Arterioscler. Thromb. Vasc. Biol.199616345546110.1161/01.ATV.16.3.4558630673
     [Google Scholar]
  40. CottoneS. VadalàA. ManganoM.T. RiccobeneR. VellaM.C. NeriA.L. MuléG. PiazzaG. AmatoF. ZagarrigoC. CerasolaG. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives.Am. J. Hypertens.200013217217610.1016/S0895‑7061(99)00169‑710701817
     [Google Scholar]
  41. CottoneS. MulèG. NardiE. LoritoM.C. GuarneriM. ArsenaR. BriolottaC. VadalàA. CerasolaG. Microalbuminuria and early endothelial activation in essential hypertension.J. Hum. Hypertens.200721216717210.1038/sj.jhh.100210917051235
     [Google Scholar]
  42. YuY. SuoL. YuH. WangC. TangH. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria.Diabetes Res. Clin. Pract.20046529510410.1016/j.diabres.2004.01.00615223221
     [Google Scholar]
  43. AgewallS. LindstedtG. FagerbergB. Independent relationship between microalbuminuria and plasminogen activator inhibitor-1 activity (PAI-1) activity in clinically healthy 58-year-old men.Atherosclerosis2001157119720210.1016/S0021‑9150(00)00706‑111427221
     [Google Scholar]
  44. ZenereB.M. ArcaroG. SaggianiF. RossiL. MuggeoM. LechiA. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria.Diabetes Care199518797598210.2337/diacare.18.7.9757555559
     [Google Scholar]
  45. YokoyamaH. SoneH. SaitoK. YamadaD. HonjoJ. HanedaM. Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes - interrelations with arterial thickness and stiffness.J. Atheroscler. Thromb.201118974475210.5551/jat.752621597231
     [Google Scholar]
  46. ItoH. NakashimaM. MeguroK. FurukawaH. YamashitaH. TakakiA. YukawaC. OmotoT. ShinozakiM. NishioS. AbeM. AntokuS. MifuneM. ToganeM. Flow mediated dilatation is reduced with the progressive stages of glomerular filtration rate and albuminuria in type 2 diabetic patients without coronary heart disease.J. Diabetes Res.201520151910.1155/2015/72812726064988
     [Google Scholar]
  47. StehouwerC.D.A. HenryR.M.A. DekkerJ.M. NijpelsG. HeineR.J. BouterL.M. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for a link between microalbuminuria and endothelial dysfunction—The Hoorn Study.Kidney Int.20046692S42S4410.1111/j.1523‑1755.2004.09211.x15485416
     [Google Scholar]
  48. ClausenP. JensenJ.S. JensenG. Borch-JohnsenK. Feldt-RasmussenB. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects.Circulation2001103141869187410.1161/01.CIR.103.14.186911294805
     [Google Scholar]
  49. DiercksG.F.H. StroesE.S.G. BovenA.J. RoonA.M. HillegeH.L. JongP.E. SmitA.J. GansR.O.B. CrijnsH.J.G.M. RabelinkT.J. GilstW.H. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects.Atherosclerosis2002163112112610.1016/S0021‑9150(01)00748‑112048129
     [Google Scholar]
  50. YunL. XuR. ZhangL. LiG. HuangS. YaoY. LiJ. The role of microalbuminuria in arterial endothelial dysfunction in hypertensive patients with carotid plaques.Int. Heart J.201455215315910.1536/ihj.13‑23224632956
     [Google Scholar]
  51. TaddeiS. VirdisA. MatteiP. GhiadoniL. SudanoI. ArrighiP. SalvettiA. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients.J. Hypertens.19951391003100810.1097/00004872‑199509000‑000108586817
     [Google Scholar]
  52. BezanteG.P. ViazziF. LeonciniG. RattoE. ContiN. BalbiM. AgostiS. DeferrariL. DeferrariG. PontremoliR. Coronary flow reserve is impaired in hypertensive patients with subclinical renal damage.Am. J. Hypertens.200922219119610.1038/ajh.2008.35119151691
     [Google Scholar]
  53. JadoulM. AounM. Masimango ImaniM. The major global burden of chronic kidney disease.Lancet Glob. Health2024123e342e34310.1016/S2214‑109X(24)00050‑038365398
     [Google Scholar]
  54. RangaswamiJ. BhallaV. BlairJ.E.A. ChangT.I. CostaS. LentineK.L. LermaE.V. MezueK. MolitchM. MullensW. RoncoC. TangW.H.W. McCulloughP.A. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A scientific statement from the American Heart Association.Circulation201913916e840e87810.1161/CIR.000000000000066430852913
     [Google Scholar]
  55. JankowskiJ. FloegeJ. FliserD. BöhmM. MarxN. Cardiovascular disease in chronic kidney disease.Circulation2021143111157117210.1161/CIRCULATIONAHA.120.05068633720773
     [Google Scholar]
  56. StevensP.E. AhmedS.B. CarreroJ.J. FosterB. FrancisA. HallR.K. HerringtonW.G. HillG. InkerL.A. KazancıoğluR. LambE. LinP. MaderoM. McIntyreN. MorrowK. RobertsG. SabanayagamD. SchaeffnerE. ShlipakM. ShroffR. TangriN. ThanachayanontT. UlasiI. WongG. YangC-W. ZhangL. LevinA. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int.20241054S117S31410.1016/j.kint.2023.10.01838490803
     [Google Scholar]
  57. MatsushitaK. van der VeldeM. AstorB.C. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: A collaborative meta-analysis of general population cohorts.Lancet20103759731207310.1016/S0140‑6736(10)60674‑520483451
     [Google Scholar]
  58. HemmelgarnB.R. MannsB.J. LloydA. JamesM.T. KlarenbachS. QuinnR.R. WiebeN. TonelliM. Alberta Kidney Disease Network Relation between kidney function, proteinuria, and adverse outcomes.JAMA2010303542342910.1001/jama.2010.3920124537
     [Google Scholar]
  59. MatsushitaK. van der VeldeM. AstorB.C. WoodwardM. LeveyA.S. de JongP.E. CoreshJ. GansevoortR.T. Chronic Kidney Disease Prognosis Consortium Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis.Lancet201037597312073208110.1016/S0140‑6736(10)60674‑520483451
     [Google Scholar]
  60. KoyeD.N. MaglianoD.J. ReidC.M. JepsonC. FeldmanH.I. HermanW.H. ShawJ.E. Risk of progression of nonalbuminuric CKD to end-stage kidney disease in people with diabetes: The CRIC (Chronic Renal Insufficiency Cohort) study.Am. J. Kidney Dis.201872565366110.1053/j.ajkd.2018.02.36429784612
     [Google Scholar]
  61. BabazonoT. HanaiK. YokoyamaY. UchiyamaK. Association between 1-year changes in urinary albumin-to-creatinine ratio and kidney disease progression in Japanese individuals with diabetes: A historical cohort study.Clin. Exp. Nephrol.202327121001100910.1007/s10157‑023‑02380‑837606804
     [Google Scholar]
  62. VermaA. SchmidtI.M. ClaudelS. PalssonR. WaikarS.S. SrivastavaA. Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria.Ann. Intern. Med.2024177446747510.7326/M23‑281438560911
     [Google Scholar]
  63. TangriN. StevensL.A. GriffithJ. TighiouartH. DjurdjevO. NaimarkD. LevinA. LeveyA.S. A predictive model for progression of chronic kidney disease to kidney failure.JAMA2011305151553155910.1001/jama.2011.45121482743
     [Google Scholar]
  64. HallanS.I. RitzE. LydersenS. RomundstadS. KvenildK. OrthS.R. Combining GFR and albuminuria to classify CKD improves prediction of ESRD.J. Am. Soc. Nephrol.20092051069107710.1681/ASN.200807073019357254
     [Google Scholar]
  65. TonelliM. MuntnerP. LloydA. MannsB.J. JamesM.T. KlarenbachS. QuinnR.R. WiebeN. HemmelgarnB.R. Alberta Kidney Disease Network Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: A cohort study.Ann. Intern. Med.20111541122110.7326/0003‑4819‑154‑1‑201101040‑0000321200034
     [Google Scholar]
  66. HsuC.Y. OrdoñezJ.D. ChertowG.M. FanD. McCullochC.E. GoA.S. The risk of acute renal failure in patients with chronic kidney disease.Kidney Int.200874110110710.1038/ki.2008.10718385668
     [Google Scholar]
  67. GramsM.E. AstorB.C. BashL.D. MatsushitaK. WangY. CoreshJ. Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury.J. Am. Soc. Nephrol.201021101757176410.1681/ASN.201001012820671214
     [Google Scholar]
  68. JamesM.T. HemmelgarnB.R. WiebeN. PannuN. MannsB.J. KlarenbachS.W. TonelliM. Alberta Kidney Disease Network Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: A cohort study.Lancet201037697582096210310.1016/S0140‑6736(10)61271‑821094997
     [Google Scholar]
  69. JamesM.T. GramsM.E. WoodwardM. ElleyC.R. GreenJ.A. WheelerD.C. de JongP. GansevoortR.T. LeveyA.S. WarnockD.G. SarnakM.J. TonelliM. HemmelgarnB.R. JamesM.T. TurinT.C. CoreshJ. MatsushitaK. GramsM. SangY. ShlipakM. SarnakM.J. KatzR. WheelerD.C. EmbersonJ. LandrayM.J. TownendJ.N. GreenJ. KirchnerH.L. PerkinsR. ChangA.R. RomundstadS. AasarødK. ØienC.M. HallanS. SmithD.H. ThorpM.L. JohnsonE.S. ChodickG. HerzelE. KatzR. ShalevV. GansevoortR.T. BakkerS.J.L. Lambers HeerspinkH.J. van der HarstP. JeeS.H. KimmH. MokY. TangriN. NaimarkD. ÄrnlövJ. LarssonA. LannfeltL. KovesdyC.P. Kalantar-ZadehK. CoreshJ. GramsM. MatsushitaK. GansevoortR.T. de JongP.E. IsekiK. LeveyA.S. SarnakM.J. StengelB. WarnockD. WoodwardM. BallewS.H. CoreshJ. GramsM. MatsushitaK. SangY. WoodwardM. CKD Prognosis Consortium A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury.Am. J. Kidney Dis.201566460261210.1053/j.ajkd.2015.02.33825975964
     [Google Scholar]
  70. Hsu, C-Y.; Chinchilli, V.M.; Coca, S.; Devarajan, P.; Ghahramani, N.; Go, A.S.; Hsu, R.K.; Ikizler, T.A.; Kaufman, J.; Liu, K.D.; Parikh, C.R.; Reeves, W.B.; Wurfel, M.; Zappitelli, M.; Kimmel, P.L.; Siew, E.D. Post-acute kidney injury proteinuria and subsequent kidney disease progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study.JAMA Intern. Med.2020180340241010.1001/jamainternmed.2019.6390
     [Google Scholar]
  71. ParvingH.H. MogensenC.E. JensenH.Æ. EvrinP.E. Increased urinary albumin-excretion rate in benign essential hypertension.Lancet197430378681190119210.1016/S0140‑6736(74)91002‑24134681
     [Google Scholar]
  72. BigazziR. BianchiS. CampeseV.M. BaldariG. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension.Nephron J.1992611949710.1159/0001868421528348
     [Google Scholar]
  73. FiciF. BakirE.A. BeyazS. MakelW. RoblesN.R. PAIT-survey—Prevalence of albuminuria in patients with diabetes and hypertension in Turkey.Prim. Care Diabetes201812655856410.1016/j.pcd.2018.08.00830327190
     [Google Scholar]
  74. PedrinelliR. Dell’OmoG. Di BelloV. PontremoliR. MarianiM. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension.J. Hum. Hypertens.2002162798910.1038/sj.jhh.100131611850764
     [Google Scholar]
  75. TsakirisA. DoumasM. LagatourasD. VyssoulisG. KarpanouE. NearchouN. KouremenouC. SkoufasP. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: The Three Areas Study in Greece (TAS-GR).Angiology200657331332010.1177/00033197060570030716703191
     [Google Scholar]
  76. AgewallS. FagerbergB. The Risk Factor Intervention Study Group Risk factors that predict development of microalbuminuria in treated hypertensive men.Angiology1996471096397210.1177/0003319796047010058873582
     [Google Scholar]
  77. PalatiniP. MorminoP. SantonastasoM. MosL. Dal FolloM. ZanataG. PessinaA.C. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study.Hypertension1998311576310.1161/01.HYP.31.1.579449391
     [Google Scholar]
  78. HataJ. FukuharaM. SakataS. ArimaH. HirakawaY. YonemotoK. MukaiN. KitazonoT. KiyoharaY. NinomiyaT. White-coat and masked hypertension are associated with albuminuria in a general population: The Hisayama Study.Hypertens. Res.2017401193794310.1038/hr.2017.7428878300
     [Google Scholar]
  79. KnightE.L. KramerH.M. CurhanG.C. High-normal blood pressure and microalbuminuria.Am. J. Kidney Dis.200341358859510.1053/ajkd.2003.5012012612982
     [Google Scholar]
  80. JiangX. SrinivasanS.R. RadhakrishnamurthyB. DalferesE.R.Jr BaoW. BerensonG.S. Microalbuminuria in young adults related to blood pressure in a biracial (black-white) population. The Bogalusa Heart Study.Am. J. Hypertens.199479_Pt_179480010.1093/ajh/7.9.7947811437
     [Google Scholar]
  81. de la SierraA. BanegasJ.R. OliverasA. GorostidiM. SeguraJ. de la CruzJ.J. ArmarioP. RuilopeL.M. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs.J. Hypertens.20123061211121610.1097/HJH.0b013e328353634e22525201
     [Google Scholar]
  82. BianchiS. BigazziR. BaldariG. SgherriG. CampeseV.M. Diurnal variations of blood pressure and microalbuminuria in essential hypertension.Am. J. Hypertens.199471232910.1093/ajh/7.1.238136107
     [Google Scholar]
  83. AfsarB. ElsurerR. Urinary albumin excretion among nondipper hypertensive patients is closely related with the pattern of nondipping.J. Am. Soc. Hypertens.20104419620210.1016/j.jash.2010.06.00420655503
     [Google Scholar]
  84. OliverasA. ArmarioP. Martell-ClarósN. RuilopeL.M. de la SierraA. Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives.Hypertension201157355656010.1161/HYPERTENSIONAHA.110.16556321220713
     [Google Scholar]
  85. AgrawalB. BergerA. WolfK. LuftF.C. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension.J. Hypertens.199614222322810.1097/00004872‑199602000‑000118728300
     [Google Scholar]
  86. YudkinJ. ForrestR. JacksonC. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.Lancet1988332861053053310.1016/S0140‑6736(88)92657‑82900920
     [Google Scholar]
  87. LjungmanS. WikstrandJ. HartfordM. BerglundG. Urinary albumin excretion — A predictor of risk of cardiovascular disease A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men.Am. J. Hypertens.19969877077810.1016/0895‑7061(96)00102‑18862223
     [Google Scholar]
  88. AgewallS. WikstrandJ. LjungmanS. FagerbergB. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus.Am. J. Cardiol.199780216416910.1016/S0002‑9149(97)00312‑39230153
     [Google Scholar]
  89. MiettinenH. HaffnerS.M. LehtoS. RönnemaaT. PyöräläK. LaaksoM. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects.Stroke199627112033203910.1161/01.STR.27.11.20338898811
     [Google Scholar]
  90. JagerA. KostenseP.J. RuhéH.G. HeineR.J. NijpelsG. DekkerJ.M. BouterL.M. StehouwerC.D.A. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study.Arterioscler. Thromb. Vasc. Biol.199919361762410.1161/01.ATV.19.3.61710073965
     [Google Scholar]
  91. HillegeH.L. FidlerV. DiercksG.F.H. van GilstW.H. de ZeeuwD. van VeldhuisenD.J. GansR.O.B. JanssenW.M.T. GrobbeeD.E. de JongP.E. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.Circulation2002106141777178210.1161/01.CIR.0000031732.78052.8112356629
     [Google Scholar]
  92. GersteinH.C. MannJ.F. YiQ. ZinmanB. DinneenS.F. HoogwerfB. HalléJ.P. YoungJ. RashkowA. JoyceC. NawazS. YusufS. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.JAMA2001286442142610.1001/jama.286.4.42111466120
     [Google Scholar]
  93. JensenJ.S. Feldt-RasmussenB. StrandgaardS. SchrollM. Borch-JohnsenK. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease.Hypertension200035489890310.1161/01.HYP.35.4.89810775558
     [Google Scholar]
  94. BigazziR. BianchiS. BaldariD. CampeseV.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension.J. Hypertens.19981691325133310.1097/00004872‑199816090‑000149746120
     [Google Scholar]
  95. WachtellK. IbsenH. OlsenM.H. Borch-JohnsenK. LindholmL.H. MogensenC.E. DahlöfB. DevereuxR.B. BeeversG. de FaireU. FyhrquistF. JuliusS. KjeldsenS.E. KristiansonK. Lederballe-PedersenO. NieminenM.S. OkinP.M. OmvikP. OparilS. WedelH. SnapinnS.M. AurupP. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.Ann. Intern. Med.20031391190190610.7326/0003‑4819‑139‑11‑200312020‑0000814644892
     [Google Scholar]
  96. GerdtsE. OkinP.M. OmvikP. WachtellK. DahlöfB. HildebrandtP. NieminenM.S. DevereuxR.B. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study.Nutr. Metab. Cardiovasc. Dis.200919530631210.1016/j.numecd.2008.12.00919303268
     [Google Scholar]
  97. PascualJ.M. RodillaE. CostaJ.A. Garcia-EscrichM. GonzalezC. RedonJ. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension.Hypertension20146461228123410.1161/HYPERTENSIONAHA.114.0427325245391
     [Google Scholar]
  98. RomundstadS. HolmenJ. HallanH. KvenildK. EllekjærH. Microalbuminuria and all-cause mortality in treated hypertensive individuals: Does sex matter? The Nord-Trøndelag Health Study (HUNT), Norway.Circulation2003108222783278910.1161/01.CIR.0000103667.27493.3214623803
     [Google Scholar]
  99. HongZ. JiangY. LiuP. ZhangL. Association of microalbuminuria and adverse outcomes in hypertensive patients: A meta-analysis.Int. Urol. Nephrol.202153112311231910.1007/s11255‑021‑02795‑w33674949
     [Google Scholar]
  100. TsioufisC. StefanadisC. ToutouzaM. KallikazarosI. ToutouzasK. TousoulisD. PitsavosC. PapademetriouV. ToutouzasP. Microalbuminuria is associated with unfavourable cardiac geometric adaptations in essential hypertensive subjects.J. Hum. Hypertens.200216424925410.1038/sj.jhh.100137911967718
     [Google Scholar]
  101. PontremoliR. RaveraM. BezanteG.P. ViazziF. NicolellaC. BerrutiV. LeonciniG. SetteM.D. BrunelliC. TomolilloC. DeferrariG. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria.J. Hypertens.1999177993100010.1097/00004872‑199917070‑0001610419073
     [Google Scholar]
  102. LiebW. MayerB. StritzkeJ. DoeringA. HenseH.W. LoewelH. ErdmannJ. SchunkertH. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population.Nephrol. Dial. Transplant.200621102780278710.1093/ndt/gfl36416880179
     [Google Scholar]
  103. PontremoliR. SofiaA. RaveraM. NicolellaC. ViazziF. TirottaA. RuelloN. TomolilloC. CastelloC. GrilloG. SacchiG. DeferrariG. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC study. Microalbuminuria: A Genoa Investigation on Complications.Hypertension19973051135114310.1161/01.HYP.30.5.11359369267
     [Google Scholar]
  104. Dell’omoG. GiorgiD. Di BelloV. MarianiM. PedrinelliR. Blood pressure independent association of microalbuminuria and left ventricular hypertrophy in hypertensive men.J. Intern. Med.20032541768410.1046/j.1365‑2796.2003.01155.x12823644
     [Google Scholar]
  105. TsioufisC.P. LambrouS.G. StefanadisC.I. AntoniadisD.I. KallikazarosI.E. PitsavosC.E. ToutouzasP.K. Microalbuminuria is associated with abnormal thoracic aortic mechanics in essential hypertension.Am. J. Cardiol.2000867797801, A910.1016/S0002‑9149(00)01087‑011018207
     [Google Scholar]
  106. LositoA. FortunatiF. ZampiI. Del FaveroA. Impaired renal functional reserve and albuminuria in essential hypertension.BMJ198829666361562156410.1136/bmj.296.6636.15623135009
     [Google Scholar]
  107. MulèG. CottoneS. VadalàA. VolpeV. MezzatestaG. MongiovìR. PiazzaG. NardiE. AndronicoG. CerasolaG. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients.J. Intern. Med.20042561222910.1111/j.1365‑2796.2004.01338.x15189362
     [Google Scholar]
  108. MulèG. CottoneS. CusimanoP. RiccobeneR. PalermoA. GeraciC. NardiE. BellaviaT. ForaciA.C. CerasolaG. The association of microalbuminuria with aortic stiffness is independent of C-reactive protein in essential hypertension.Am. J. Hypertens.200922101041104710.1038/ajh.2009.13219629049
     [Google Scholar]
  109. SarafidisP. Use of ACEi/ARBs, SGLT2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD.Clin. Kidney J.2024172sfae01410.1093/ckj/sfae014
     [Google Scholar]
  110. GersteinH.C. YusufS. MannJ.F.E. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy.Lancet2000355920025325910.1016/S0140‑6736(99)12323‑710675071
     [Google Scholar]
  111. AsselbergsF.W. DiercksG.F.H. HillegeH.L. van BovenA.J. JanssenW.M.T. VoorsA.A. de ZeeuwD. de JongP.E. van VeldhuisenD.J. van GilstW.H. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.Circulation2004110182809281610.1161/01.CIR.0000146378.65439.7A15492322
     [Google Scholar]
  112. RuggenentiP. FassiA. IlievaA.P. BrunoS. IlievI.P. BruseganV. RubisN. GherardiG. ArnoldiF. GanevaM. Ene-IordacheB. GaspariF. PernaA. BossiA. TrevisanR. DodesiniA.R. RemuzziG. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators Preventing microalbuminuria in type 2 diabetes.N. Engl. J. Med.2004351191941195110.1056/NEJMoa04216715516697
     [Google Scholar]
  113. RuggenentiP. FassiA. IlievaA.P. IlievI.P. ChiurchiuC. RubisN. GherardiG. Ene-IordacheB. GaspariF. PernaA. CravediP. BossiA. TrevisanR. MotterliniN. RemuzziG. BENEDICT-B Study Investigators Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.J. Hypertens.201129220721610.1097/HJH.0b013e32834069bd21243736
     [Google Scholar]
  114. PatelA. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.Lancet.200737095908294010.1016/S0140‑6736(07)61303‑8
     [Google Scholar]
  115. ParvingH.H. LehnertH. Bröchner-MortensenJ. GomisR. AndersenS. ArnerP. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N. Engl. J. Med.20013451287087810.1056/NEJMoa01148911565519
     [Google Scholar]
  116. VibertiG. WheeldonN.M. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.Circulation2002106667267810.1161/01.CIR.0000024416.33113.0A12163426
     [Google Scholar]
  117. MakinoH. HanedaM. BabazonoT. MoriyaT. ItoS. IwamotoY. KawamoriR. TakeuchiM. KatayamaS. INNOVATION Study Group Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.Diabetes Care20073061577157810.2337/dc06‑199817389334
     [Google Scholar]
  118. MenneJ. IzzoJ.L.Jr ItoS. JanuszewiczA. KatayamaS. ChatzykirkouC. MimranA. RabelinkT.J. RitzE. RuilopeL.M. RumpL.C. VibertiG. HallerH. ROADMAP investigators Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.J. Hypertens.201230481181810.1097/HJH.0b013e328351856d22418908
     [Google Scholar]
  119. DahlöfB. DevereuxR.B. KjeldsenS.E. JuliusS. BeeversG. de FaireU. FyhrquistF. IbsenH. KristianssonK. Lederballe-PedersenO. LindholmL.H. NieminenM.S. OmvikP. OparilS. WedelH. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet20023599311995100310.1016/S0140‑6736(02)08089‑311937178
     [Google Scholar]
  120. IbsenH. WachtellK. OlsenM.H. Borch-JohnsenK. LindholmL.H. MogensenC.E. DahlöfB. DevereuxR.B. de FaireU. FyhrquistF. JuliusS. KjeldsenS.E. Lederballe-PedersenO. NieminenM.S. OmvikP. OparilS. WanY. LIFE substudy Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.J. Hypertens.20042291805181110.1097/00004872‑200409000‑0002615311110
     [Google Scholar]
  121. NataleP. PalmerS.C. NavaneethanS.D. CraigJ.C. StrippoliG.F.M. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.Cochrane Libr.202420245CD00625710.1002/14651858.CD006257.pub238682786
     [Google Scholar]
  122. BakrisG.L. RuilopeL. LocatelliF. PtaszynskaA. PieskeB. de ChamplainJ. WeberM.A. RazI. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial.Kidney Int.200772787988510.1038/sj.ki.500245517667984
     [Google Scholar]
  123. MannJ.F.E. SchmiederR.E. McQueenM. DyalL. SchumacherH. PogueJ. WangX. MaggioniA. BudajA. ChaithiraphanS. DicksteinK. KeltaiM. MetsärinneK. OtoA. ParkhomenkoA. PiegasL.S. SvendsenT.L. TeoK.K. YusufS. ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Lancet2008372963854755310.1016/S0140‑6736(08)61236‑218707986
     [Google Scholar]
  124. RuggenentiP. CortinovisM. ParvanovaA. TrilliniM. IlievI.P. BossiA.C. BelvisoA. AparicioM.C. TrevisanR. RotaS. PernaA. PeracchiT. RubisN. MartinettiD. PrandiniS. GaspariF. CarraraF. De CosmoS. TonoloG. MangiliR. RemuzziG. VARIETY Study Organization Preventing microalbuminuria with benazepril, valsartan, and benazepril–valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.PLoS Med.2021187e100369110.1371/journal.pmed.100369134260595
     [Google Scholar]
  125. CurrieG. TaylorA.H.M. FujitaT. OhtsuH. LindhardtM. RossingP. BoesbyL. EdwardsN.C. FerroC.J. TownendJ.N. van den MeirackerA.H. SaklayenM.G. OveisiS. JardineA.G. DellesC. PreissD.J. MarkP.B. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.BMC Nephrol.201617112710.1186/s12882‑016‑0337‑027609359
     [Google Scholar]
  126. NielsenS.E. PerssonF. FrandsenE. SugayaT. HessG. ZdunekD. ShjoedtK.J. ParvingH-H. RossingP. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.Diabet. Med.2012298e184e19010.1111/j.1464‑5491.2012.03585.x22268920
     [Google Scholar]
  127. ZiaeeA. VaeziA.A. OveisiS. JavadiA. HashemipourS. KazemifarA.M. Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial.Caspian J. Intern. Med.20134264865324009953
     [Google Scholar]
  128. ChenY. LiuP. ChenX. LiY. ZhangF. WangY. Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy.Am. J. Med. Sci.2018355541842410.1016/j.amjms.2018.01.01729753370
     [Google Scholar]
  129. AndoK. OhtsuH. UchidaS. KanameS. ArakawaY. FujitaT. EVALUATE Study Group Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.Lancet Diabetes Endocrinol.201421294495310.1016/S2213‑8587(14)70194‑925466242
     [Google Scholar]
  130. El MokademM. Abd El HadyY. AzizA. A prospective single-blind randomized trial of ramipril, eplerenone and their combination in type 2 diabetic nephropathy.Cardiorenal Med.202010639240110.1159/00050867032998143
     [Google Scholar]
  131. AgarwalR. KolkhofP. BakrisG. BauersachsJ. HallerH. WadaT. ZannadF. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.Eur. Heart J.202142215216110.1093/eurheartj/ehaa73633099609
     [Google Scholar]
  132. BakrisG.L. AgarwalR. AnkerS.D. PittB. RuilopeL.M. RossingP. KolkhofP. NowackC. SchloemerP. JosephA. FilippatosG. FIDELIO-DKD Investigators Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N. Engl. J. Med.2020383232219222910.1056/NEJMoa202584533264825
     [Google Scholar]
  133. PittB. FilippatosG. AgarwalR. AnkerS.D. BakrisG.L. RossingP. JosephA. KolkhofP. NowackC. SchloemerP. RuilopeL.M. FIGARO-DKD Investigators Cardiovascular events with finerenone in kidney disease and type 2 diabetes.N. Engl. J. Med.2021385242252226310.1056/NEJMoa211095634449181
     [Google Scholar]
  134. Skrabic, R.; Kumric, M.; Vrdoljak, J.; Rusic, D.; Skrabic, I.; Vilovic, M.; Martinovic, D.; Duplancic, V.; Kurir, T.T.; Bozic, J. SGLT2 inhibitors in chronic kidney disease: From mechanisms to clinical practice.Biomedicines20221010245810.3390/biomedicines10102458
     [Google Scholar]
  135. WaijerS.W. XieD. InzucchiS.E. ZinmanB. Koitka-WeberA. MattheusM. von EynattenM. InkerL.A. WannerC. HeerspinkH.J.L. Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: A post hoc analysis of the empa-reg outcome trial.J. Am. Heart Assoc.2020918e01697610.1161/JAHA.120.01697632893717
     [Google Scholar]
  136. NealB. PerkovicV. MahaffeyK.W. de ZeeuwD. FulcherG. EronduN. ShawW. LawG. DesaiM. MatthewsD.R. CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes.N. Engl. J. Med.2017377764465710.1056/NEJMoa161192528605608
     [Google Scholar]
  137. NeuenB.L. OhkumaT. NealB. MatthewsD.R. de ZeeuwD. MahaffeyK.W. FulcherG. LiQ. JardineM. OhR. HeerspinkH.L. PerkovicV. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program.J. Am. Soc. Nephrol.201930112229224210.1681/ASN.201901006431530577
     [Google Scholar]
  138. WiviottS.D. RazI. BonacaM.P. MosenzonO. KatoE.T. CahnA. SilvermanM.G. ZelnikerT.A. KuderJ.F. MurphyS.A. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. RuffC.T. Gause-NilssonI.A.M. FredrikssonM. JohanssonP.A. LangkildeA.M. SabatineM.S. DECLARE–TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N. Engl. J. Med.2019380434735710.1056/NEJMoa181238930415602
     [Google Scholar]
  139. MosenzonO. WiviottS.D. HeerspinkH.J.L. DwyerJ.P. CahnA. GoodrichE.L. RozenbergA. SchechterM. YanuvI. MurphyS.A. ZelnikerT.A. Gause-NilssonI.A.M. LangkildeA.M. FredrikssonM. JohanssonP.A. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. SabatineM.S. RazI. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58.Diabetes Care20214481805181510.2337/dc21‑007634233928
     [Google Scholar]
  140. PerkovicV. JardineM.J. NealB. BompointS. HeerspinkH.J.L. CharytanD.M. EdwardsR. AgarwalR. BakrisG. BullS. CannonC.P. CapuanoG. ChuP.L. de ZeeuwD. GreeneT. LevinA. PollockC. WheelerD.C. YavinY. ZhangH. ZinmanB. MeiningerG. BrennerB.M. MahaffeyK.W. CREDENCE Trial Investigators Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N. Engl. J. Med.2019380242295230610.1056/NEJMoa181174430990260
     [Google Scholar]
  141. OshimaM. NeuenB.L. LiJ. PerkovicV. CharytanD.M. de ZeeuwD. EdwardsR. GreeneT. LevinA. MahaffeyK.W. De NicolaL. PollockC. RosenthalN. WheelerD.C. JardineM.J. HeerspinkH.J.L. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial.J. Am. Soc. Nephrol.202031122925293610.1681/ASN.202005072332998938
     [Google Scholar]
  142. JongsN. GreeneT. ChertowG.M. McMurrayJ.J.V. LangkildeA.M. Correa-RotterR. RossingP. SjöströmC.D. StefanssonB.V. TotoR.D. WheelerD.C. HeerspinkH.J.L. DAPA-CKD Trial Committees and Investigators Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.Lancet Diabetes Endocrinol.202191175576610.1016/S2213‑8587(21)00243‑634619106
     [Google Scholar]
  143. Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; Ng, S.Y.A.; Sammons, E.; Zhu, D.; Hill, M.; Stevens, W.; Wallendszus, K.; Brenner, S.; Cheung, A.K.; Liu, Z-H.; Li, J.; Hooi, L.S.; Liu, W.; Kadowaki, T.; Nangaku, M.; Levin, A.; Cherney, D.; Maggioni, A.P.; Pontremoli, R.; Deo, R.; Goto, S.; Rossello, X.; Tuttle, K.R.; Steubl, D.; Petrini, M.; Massey, D.; Eilbracht, J.; Brueckmann, M.; Landray, M.J.; Baigent, C.; Haynes, R. Empagliflozin in patients with cronic kdney dsease.N. Engl. J. Med.2023388211712710.1056/NEJMoa220423336331190
     [Google Scholar]
  144. TangriN. RastogiA. Nekeman-NanC. HongL.S. OzakiA. FranzénS. SofueT. Dapagliflozin utilization in chronic kidney disease and its real-world effectiveness among patients with lower levels of albuminuria in the USA and Japan.Adv. Ther.20244131151116710.1007/s12325‑023‑02773‑x38240949
     [Google Scholar]
  145. FerreiraJ.P. ZannadF. ButlerJ. FilippatosG. PocockS.J. BrueckmannM. SteublD. SchuelerE. AnkerS.D. PackerM. Association of empagliflozin treatment with albuminuria levels in patients with heart failure.JAMA Cardiol.20227111148115910.1001/jamacardio.2022.292436129693
     [Google Scholar]
  146. AlicicR.Z. CoxE.J. NeumillerJ.J. TuttleK.R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.Nat Rev Nephrol.202017422724410.1038/s41581‑020‑00367‑2
     [Google Scholar]
  147. YuanD. SharmaH. KrishnanA. VangavetiV.N. MalabuU.H. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta-analysis.Diabetes Obes. Metab.20222491869188110.1111/dom.1477635589615
     [Google Scholar]
  148. TuttleK.R. LakshmananM.C. RaynerB. BuschR.S. ZimmermannA.G. WoodwardD.B. BotrosF.T. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.Lancet Diabetes Endocrinol.20186860561710.1016/S2213‑8587(18)30104‑929910024
     [Google Scholar]
  149. GersteinH.C. ColhounH.M. DagenaisG.R. DiazR. LakshmananM. PaisP. ProbstfieldJ. BotrosF.T. RiddleM.C. RydénL. XavierD. AtissoC.M. DyalL. HallS. Rao-MelaciniP. WongG. AvezumA. BasileJ. ChungN. CongetI. CushmanW.C. FranekE. HancuN. HanefeldM. HoltS. JanskyP. KeltaiM. LanasF. LeiterL.A. Lopez-JaramilloP. Cardona MunozE.G. PiragsV. PogosovaN. RaubenheimerP.J. ShawJ.E. SheuW.H.H. Temelkova-KurktschievT. AbellaM. AlebuenaA. AlmagroS. AmorosoE. AnadonP. AndreuE. AristimuñoG. ArzadunM. BarbieriM. BarcudiR. BartolacciI. BolobanichG. BordonavaA. Bustamante LabartaM. BustosB. CaccavoA. CaminoA. CanteroM. CarignanoM. CartasegnaL. CipulloM. CommendatoreV. ConosciutoV. CostamagnaO. CrespoC. CuelloJ. CuneoC. CusimanoS. DeanS. DituroC. DominguezA. FarahM. FernandezA. FernandezF. FerrariA. FlammiaP. FuentealbaJ. GallardoK.B. GarciaC. Garcia DuranR. GarridoM. GavicolaR. GerbaudoC. GilliG. GiottoA.P. Godoy BolzánP. Gomez VilamajoO. GuerlloyF. GuridiC. Gutierrez GarridoN. HasbaniE. HermidaS. HominalM. HrabarA. IngaramoA. IzzicupoA. KrynskiM. LagruttaM. LanchiottiP. LangheM. LeonardV. LlanosJ. Lopez SantiR. LowensteinJ. LuquezC. MackinnonI. ManaM. ManzurS. MarinoJ. MartellaC. MartinezR. MatiasR. MatkovichJ. MeritanoM. MontañaO. MulazziM. OchoaJ. PaterliniG. PelagaggeM. Peralta LopezM.E. PradoA. PruyasL. RaccaM. RicottiC. RodriguezC. Romero VidomlanskyM. RonderosR. SadowskiA.L. SalaJ. SánchezA. SantoroA. SchiaviL. SeinM. SerniaV. SerraL. SicerM. SmithT. SosoL. SposettiG. SteinacherA. StivalJ. TedescoJ. ToninH. TortoloM. UllaM. VallejosJ. VicoM. VirgillitoL. ViscoV. VogelD. WaismanF. ZaidmanC. ZucchiattiN. BadshahI. CohenN. ColmanP. ColquhounD. DavisT. FourlanosS. FulcherG. HamlynJ. HaywoodC. HockingS. HuchinsonM. JeffriesW. KylM. LoC. MahP.M. MakepeaceA. MaropeD. NanayakkarN. NankervisA. PalmerN. PalolusB. PillaiS. PriceS. PriceS. ProiettoJ. ReutensA. RodrigoN. SheikhA. SmithG. SoM. SoldatosG. StuckeyB. SumithranP. TeedeH. VoraP. WilliamsL. AbibE. Adão PoçoC. AlvesÉ.F. Andreatta Bernardi BareaJ. Avezum OliveiraL. CastroD.L.C. Correa da CruzI. CostaM. CruzI. CunhaS. Da SilvaM.A.V. de Carvalho Camara BonaR. de PaulaB. EliaschewitzF. FazolliG. Ferreira FilhoC.A. FortesJ. FrançaC. FrancoD.R. GenestretiP.R. GiorgetoF. GonçalvesR.M. GrossmanM.E. Henrique MarcelinoA.C. HernandesM. HortaA. JaegerC. KaneblaiM. Kauffman RutenbergC. Kerr SaraivaJ.F. LemosM.A. MaiaL. ManentiE.R. MarquesM. Melissa ValerioC. MoreiraR. MothéF. MoucoO.M. MouraP. Moura JorgeJ.C. NakashimaC. NakazoneM. NapoliT. NunesC. Nunes SallesJ.E. OliveiraK. OliveiraM. PantanoG.S. PetriF. PiazzaL. PiresA.C. PizzatoP. PrataS. PrecomaD. RechR. ReisG. ReisH. ResendeE. Ribas FortesJ. RodovalhoS. Rossi dos SantosF. SallesJ.E. SampaioC.R. SantosT. Santos dos SantosV. Silva e QuadrosT. SilveiraD. SiqueiraK.N. TeireiraM. UeharaM. ValerioC. ViannaH. VidottiM.H. ViscontiG.L. ZanellaM.T. AndreevaV. BorisovR. BotushanovN. DimitrovG. DimovaK. DragoychevT. GrigorovaV. GushterovaV. IvanovI. KocelovaT. KurktschievD. MiletievaM. Nenkova-GugushevaN. PanchevaR. PavlovaM. RaevD. SpasovaV. StoikovA. TroevD. YanevT. Yoncheva-MihaylovaM. AbitbolA. AjalaB. AlguwaihesA. ArdilouzeJ-L. Aris-JilwanN. ArnaoutA. AronsonR. AslamN. BabinS. BailargeonJ-P. BaileyA. BajajH. BeauchesneC. BecaS. BelangerA. BellA. BellabarbaD. BerardL. BerenbaumB. BergeronV. BerlingieriJ. BernierF. BisharaP. BlankD. BlumerI. BraultS. BretonD. CarpentierA. ChaJ. ChandraP. ChiassonJ-L. ConwayJ.R. CoutureG. CoutureN. DagenaisG. DattaD. D’IgnazioG. DumasR. FayD. FrechetteA. FrenetteL. FungD. GagnonN. GalterM. GaronJ. GauthierJ.S. GeadahC. GilbertJ. GirardR. GoldenbergR. GrossmanL.D. GuptaN. HalleJ-P. HivertM-F. HoudeG. HouldenR. HramiakI. JablonskiT. JainA.J. KhandwalaH. KhoslaM. LachanceC. LaflammeE. LangloisM-F. LariveeL. LiutkusJ. LochnanH. MalikS. McDonaldC. MehtaP. MihailidisJ. MilotA. NarulaP. NaultP. NayarA. NiskerW. OuelletG. PalardyJ. PatelM. PaulT. PedersenS. PerronP. PesantM-H. PoirierP. PoulinM-C. PunthakeeZ. RehmanW. RossS. SagarP. SalibaN. SandlerS. SchiffrinA. SchlosserR. Seth-SharmaA. ShermanM. SionitD. SivakumarT. SotoJ. St-AmourE. SteenO. SussmanJ. TelnerA. TobeS. Twum-BarimaD-Y. Van ZantenA. VanRossumN. VecchiarelliJ. WardR. WessengelJ. WeisnagelS. WildermanI. WooV. YakubovichN. YaleJ-F. YaredZ. AcevedoM. AguirreM.L. AizmanA. BarrosoM.S. CobosL. Danin VargasA. DescalziB. GodoyG. GrumbergE. LahsenR. LarenasG. OrtizE. ParedesJ. PotthoffS. RetamalE. RojasL. SalgadoM. SantibanezC. SolisC. StokinsB. AcciniJ. AcebedoJ. Agudelo BaenaL.M. AlarconS. AngelJ. ArcosE. Aroca MartinezM. AtuestaL. BalagueraJ. BallestasD. BarreraS.I. Barrios ReyesR. BayonaA. BermudezA. BernalD.Z. BlanquicettM. BravoV. BuenoW. Burbano DelgadoA. CadenaA. CadenaA. CaicedoS. CeleminC. ConsuegraR. Contreras PimientaC. CorredorK.J. CureC. De La Hoz RuedaL.D. DelgadoE. DiazS. DiegoM. DonadoA. Encinales SanabriaW. EscobarJ. EscorciaG. ForeroL. FuentesL. GarciaM. Garcia LozadaH. Garcia OrtizL. GiraldoA. Gomez GonzalezL. GranadaJ. GutierrezC. HenaoN. HernandezE. Herrera UejbeO.M. Higuera CobosJ.D. Ibarra GómezJ. JaimesE.H. JaramilloM. JaramilloN. Jaramillo GomezC. Jaramillo SanchezM. Jarava DuránI. Lopez CeballosC. MadridC. María AmasthaE. MercadoJ. MolinaD.I. Molina SotoJ. MontoyaC. MoralesA. MuñozC. OrozcoL.A. OsorioO. Palmera SanchezJ.M. PeñaA. PerezJ. Perez AgudeloJ. Pérez AmadorG. PertuzC. PosadaI. PuertaC. QuinteroA. QuirozD. RendonC. ReyesA. ReyesA. RipollD. RiveraC. RochaM. RodriguezJ.F. Rodriguez VillanuevaK.A. Rodriguez ZabalaJ.E. RojasS. RomeroM. RoseroR. Rosillo CardenasA.R. RuedaL. SanchezG. SanchezT. Sotomayor HerazoA. SuarezM. TorresM. TrujilloF. UrinaM. Van StrahlenL. VelandiaC. Velasquez GuzmanC. VelazquezE. Vidal PradaT. Yepez AlvaranJ.P. ZarateD. AndelovaJ. BenesovaR. BuzovaB. CechV. ChodovaI. ChouraM. DufkaA. GamovaA. GorgolJ. HalaT. HavlovaH. HlavkovaD. HoranskaP. Ilcisin-ValovaJ. JenickovaP. JerabekO. KantorovaI. KolomaznikovaK. KopeckovaI. KopeckovaM. LinhartK. LinhartT. MalechaJ. MalicherovaE. NeubauerovaD. OznerovaM. PartysR. PederzoliovaE. PetrusovaM. PrymkovaV. RacickaE. ReissovaI. RoderovaE. StanekL. StriovaA. SvarcovaD. SvobodaP. Szeghy MalicharovaE. UrgeJ. VeselyL. WasserburgerB. WasserburgerovaH. ZahumenskyE. ZamrazilV. AlawiH. AnastasiadisE. AxthelmE. BielerT. BuhrigC. DegtyarevaE. DellannaF. DerwahlK-M. DiesselS. DogiamiB. Dorn-WeitzelK. ErnstM. FaulmannG. FetscherB. ForstT. Freyer-LahresG. FunkeK. GanzX. GleixnerC. HanefeldC. HeinrichsS. HellebergS. HenkelE. HetzelG.R. HoffmannC. JacobF. JacobS. JohnF. JonczykA. KamkeW. KleinC. KleinhardtM. KleophasW. KoschC. KreutzmannK. KühnA. Lee-BarkeyY.H. LierA. MaatoukS. MinnichJ. MitryM. MuessigI. NiculaD. NiemannM. NothroffJ. OttP. PfuetznerA. PfütznerA. PistroschF. PohlW. ProchazkovaZ. RetkowskaM. RosinH. SachsenheimerD. SamerH. SanuriM. SchaeferA. SchaperF. SchulzeE-D. SchulzeM. SchumannM. SegietT. SowaV. StahlH-D. SteinfeldtF. TeigeM. TriebB. TschoepeD. UebelP. WarkenB. WeigmannI. WeylandK. WilhelmK. BaloT. BalsayM. BendeI. BezzeghK. BirkusZ. BudayB. CsomaiM. DeakL. DezsoE. FaludiP. FaluvegiM. FazekasI. FeherA. FejerC. FintaE. FulczA. GaalZ. GurzoM. HatiK. HerczegG. JozsefI. JuhaszM. KeltaiK. KoranyiL. KulcsarE. KunK. LaczkoA. Literáti-NagyB. MezoI. MilederM. MoriczI. NagyK. NagybaczoniB. NemethC. OzeA. PauerJ. PeterfaiE. PolocsanyiB. PoorF. ReiberI. SalamonC. SebestyenJ. TorokI. TuuM. VargaA. VassV. AhnC.M. AhnC. ByungWonP. ChangH-J. ChangK. ChoiE-Y. ChoiH.S. ChungJ-W. HongB-K. HongY.J. HyonM.S. JeongM.H. KangS. KimB-K. KimJ-H. KimJ.H. KimK-S. KimK-S. KimM.H. KimP-J. KimS-K. KimY-S. KimY.K. KohY.S. KwonH.M. LeeB.K. LeeB-W. LeeJ.B. LeeM-M. LimY-M. MinP.K. ParkJ.S. ParkJ. ParkK.H. ParkS. PyunW.B. RimS.J. RyuD-R. SeoH-S. SeungK.B. ShinD-H. SimD.S. YoonY.W. AndersoneI. BabickaK. BalcereI. BaronsR. CapkovskaI. GeldnereK. GriganeI. JegereB. LagzdinaI. MoraL. PastareS. RitenbergaR. RomanovaJ. SakniteI. SidlovskaN. SokolovaJ. SteinaS. StrizkoI. TeterovskaD. VizinaB. BarsieneL. BelozarieneG. Daugintyte-PetrusieneL. DrungilieneN. GarsvieneN. GrigieneA. GrizasV. JocieneV. KalvaitieneD. KaupieneJ. KavaliauskieneJ. KozlovieneD. LaptevaI. ManeikieneB. MarcinkevicieneJ. MarkauskieneV. MeilunieneS. NorkusA. NorvilieneR. PetrenkoV. RadzevicieneR. SakalyteG. UrbonasG. UrbutieneS. VasiliauskasD. VelickieneD. AguilarC. AlcocerM. Avalos-RamirezJ.A. Banda-ElizondoR. Bricio-RamirezR. Cardenas MejiaK. CavazosF. ChapaJ. CienfuegosE. De la PeñaA. de la Peña TopeteG. De los Rios IbarraM.O. EliasD. Flores-MorenoC. Garcia HernandezP. GonzalezL.G. Guerra MoyaR.L. Guerra-LopezA. Hernandez BaylonR. Herrera ColoradoC. Herrera-MarmolejoM. Islas-PalaciosN. LopezE. LopezF. Lopez AlvaradoA. Luna CeballosR.I. Morales VillegasE. Moreno-VirgenG. Parra PerezR.L. Pascoe GonzalezS. Peralta-CantuI. PrevinR. RamirezR. RamirezR. Ramos ZavalaM.G. RodriguezM. Salgado-SedanoR. Sanchez-AguilarA.C. Santa Rosa FrancoE. Sauque-ReynaL. Suarez OteroR. TorresI. Velarde-HarnandezE. VillagordoaJ. Villeda-EspinozaE. Vital-LopezJ. Zavala- BelloC.J. BakerJ. Barrington-WardE. BrownlessT. CarrollR. CarsonS. ChoeM. CorinA. CorleyB. CutfieldR. DalamanN. DixonP. DruryP. DysonK. FlorkowskiC. FordM. FrengleyW. HelmC. KatzenC. KerrJ. KhanolkarM. KimD. KoopsR. KrebsJ. LeikisR. LowK. LuckeyA. LukeR. MacaulayS. MarksR. McNamaraC. Millar-CooteD. MillerS. MottersheadN. ReidJ. RobertsonN. RosenI. RoweD. SchmiedelO. ScottR. SebastianJ. SheahanD. StiebelV. TernouthI. TofieldC. VenterD. WilliamsM. WilliamsM. WuF. YoungS. ArciszewskaM. BochenekA. BorkowskiP. BorowyP. ChrzanowskiT. CzerwinskiE. DwojakM. GrodzickaA. JaniecI. JarugaJ. Jazwinska-TarnawskaE.K. JedynastyK. Juzwiak-CzapiewskaD. Karczewicz-JanowskaJ. KoniecznyJ. KoniecznyM. KorolM. KozinaM. KrzyzagorskaE. Kucharczyk-PetrykaE. LazR. MajchrzakA. MrozowskaZ. MularczykM. NowackaE. PeczynskaJ. PetrykaR. PietrzakR. Pisarczyk-WizaD. RozanskaA. RuzgaZ. RzeszotarskaE. SachaM. SekulskaM. Sidorowicz-BialynickaA. StasinskaT. Strzelecka-SosikA. SwierszczT. SzymkowiakK.M. TurowskaO. WisniewskaK. WizaM. WozniakI. ZelazowskaK. Ziolkowska-GawronB. Zytkiewicz-JarugaD. AlbotaA. AlexandruC. AvramR. BalaC. BarbontaD. BarbuR. BraicuD. CalutiuN. CatrinoiuD. CerghizanA. CiorbaA. CraciunA. DorosR. DumaL. DumitracheA. FerariuI. Ferician MozaA. GherganA. GhiseG. GraurM. GribovschiM. MihaiB. MihalacheL. MihalceaM. MindrescuN. MorosanuM. MorosoanuA. MotaM. MozaA. NafornitaV. NateaN. NicodimS. NitaC. OnacaA. OnacaM. PopC. PopL. PopaA. PopescuA. PrunaL. RomanG. RosuM. SimaA. SipciuD. Sitterli-NateaC.N. SzilagyiI. TapuricaM. TaseA. TutescuA-C. VanghelieL. VerdeI. VladA. ZarnescuM. AkhmetovR. AllenovaI. AvdeevaI. BaturinaO. BiserovaI. BokovinN. BondarI. BurovaN. ChufenevaG. ChumachekE. DemidovaM. DeminA. DrobyshevaV. EgorovaI. EsenyanL. GeligE. GilyarevskyS. GolshmidM. GoncharovA. GorbunovaA. GordeevI. GorelyshevaV. GoryunovaT. GrebenshchikovaI. IlchenkoR. IvannikovaM. KarabalievaS. KarpeevaJ. KhaykinaE. KobalavaZ. KononenkoI. KorolikO. KorshunovaA. KostenkoV. KrasnopevtsevaI. KrylovaL. KulkovaP. KuzminaI. LedyaevaA. LevashovS. LokhovininaN. LvovV. MartirosyanN. NedogodaS. NilkR. OsmolovskayaY. PanovA. ParamonovaO. PavlovaE. PekarevaE. PetuninaN. PonamarevaS. ReshedkoG. SalasyukA. SepkhanyanM. SerebrovA. ShabelnikovaO. SkvortsovA. SmirnovaO. SpiridonovaO. StrogovaS. TaratukhinE. TereschenkoS. TrukhinaL. TsarkovaO. TsomaV. TumarovF. TyanN. TyurinaT. VillevaldeS. YankovayaE. ZarutskayaL. ZenkovaE. BadatA. BesterF. BlignautS. BlomD. BooysenS. BoydW. BriceB. BrownS. BurgessL. CawoodR. CoetzeeK. ConradieH. CronjeT. de JongD. EllisG. EmanuelS. EngelbrechtI. FoulkesS. FourieD. GibsonG. GovenderT. HansaS. HemusA.C. HendricksF. HeradienM. HolmgrenC. HoosainZ. HorakE. HowardJ. ImminkI. JanariE. JivanD. KlusmannK. LabuschagneW. LaiY. LatiffG. LombaardJ. LotteringH. MeedingR. MiddlemostS. MithaH. MithaI. MkhwanaziS. MoodleyR. MurrayA. MusungaieD. OsmanY. PeaceyK. Pillay-RamayaL. PretoriusC. ProzeskyH. SarvanM. ScholtzE. SebestenyA. SkinnerB. SkrikerM. SmitM. StapelbergA-M. SwanepoelN. UrbachD. van AswegenD. van ZylF. Van ZylL. VenterE. WadvallaS. WingJ. WolmaransK. AbreuC. AguilàP. AguileraE. AlonsoN. AlvarezC. CajasP. CastroJ.C. CodinachsR. ContrerasJ. CovesM.J. FajardoC. FerrerJ.C. FontN. GarciaM. GilM.A. GomezF. GomezL.A. GonzalbezJ. GrieraJ.L. MasmiquelL. MauricioD. Narejos PerezS. NicolauJ.A. Noheda ContrerasO. OlivanJ. OlivaresJ. OrtegaE. PelliteroS. PertusaS. RiusF. RodriguezI. Sánchez-JuanC. SantosD. SoldevilaB. SubiasD. TernsM. TrescoliC. VilaplanaJ. VillanuevaA. AlboJ. AntusK. AxelssonM. BergströmL. Binsell-GerdinE. BomanK. BotondF. DotevallA. GraipeA. JarnetC. KaminskaJ. KempeA. KorhonenM. LinderfalkC. LiuB. LjungstroemK. LjungströmK. MalmqvistL. MellbinL. MooeT. NicolP. NorrbyA. OhlssonA. RosengrenA. SaafJ. SalmonssonS. StrandbergO. SvenssonK-A. TengmarkB-O. TsatsarisG. UlvenstamA. VaskoP. ChangC-T. ChangH-M. ChenJ-F. ChenT-P. ChungM-M. FuC-P. HsiaT-L. HuaS-C. KuoM-C. LeeC. LeeI-T. LiangK-W. LinS.Y. LuC-H. MaW-Y. PeiD. ShenF-C. SuC-C. SuS-W. TaiT-S. TsaiW-N. TsaiY-T. TungS-C. WangJ-S. YuH-I. Al-QaissiA. ArutchelvamV. AtkinS. AuS. AyeM.M. BainS. BejnariuC. BellP. BhatnagarD. BilousR. BlackN. BrennanU. BrettB. BujanovaJ. ChowE. CollierA. CombeA. CourtneyC. CourtneyH. CrothersJ. EavisP. ElliottJ. FebbraroS. FinlaysonJ. GandhiR. GillingsS. HamlingJ. HarperR. HarrisT. HassanK. HellerS. JaneA. JavedZ. JohnsonT. JonesS. KennedyA. KerrD. KilgallonB. KonyaJ. LindsayJ. Lomova-WilliamsL. LookerH. MacFarlaneD. MacruryS. MalikI. McCrimmonR. McKeithD. McKnightJ. MishraB. MukhtarR. MulliganC. O’KaneM. OlatejuT. OrpenI. RichardsonT. RooneyD. RossS.B. SathyapalanT. SiddaramaiahN. SitL.E. StephensJ. TurtleF. WakilA. WalkinshawE. AliA. AndersonR. ArakakiR. ArefO. ArianiM.K. ArkinD. BanarerS. BarchiniG. BhanA. BranchK. BrautigamD. BrietzkeS. BrinasM. BritoY. CarterC. CasagniK. CasulaS. ChakkoS. CharatzS. ChildressD. ChowL. ChusteckaM. ClarkeS. CohenL. CollinsB. Colon VegaG. Comulada-RiveraA. Cortes-MaisonetG. DavisM. de SouzaJ. DesouzaC. DinnanM. Duffy-HidalgoB. DunnB. DunnJ. ElmanM. FelicettaJ. FinkelsteinS. Fitz-PatrickD. FlorezH. ForkerA. FowlerW. FredricksonS. FreedmanZ. Gainey NarronB. Gainey-FerreeK. GardnerM. GastelumC. GiddingsS. GillespieE. GimnessM.P. GoldsteinG. GomesM. GomezN. GormanT. GoswamiK. GravesA. HackingS. HallC. HansonL. HarmanS. HeberD. HenryR. HinerJ. HirschI. HollanderP. HookerT. HorowitzB. HosteL. HuangL. HuynhM. HymanD. IdrissS. IranmaneshA. KarounosD. KashyapM. KatzL. KayeW. KhaitonY. KhardoriR. KitchenT. KleinA. KnffemW. KosiborodM. KreglingerN. KrugerD. KumarA. LaboyI. LarrabeeP. LarrickL. LawsonD. LedetM. LenhardJ. LevyJ. LiG. LiZ. LiebD. LimcoliocA. Lions-PattersonJ. LorberD. LorchD. LorrelloM. LuP. LucasK.J. MaS-L. MacAdamsM. MageeM. MagnoA. MahakalaA.R. MarksJ. McCallA. McClanahanW.Jr McClaryC. MelendezL. MelishJ. MichaudD. MillerC. MillerN. MoraP. MotenM. MudaliarS. MyrickG. NarayanP. NassifM. NeriK. NewtonT. NiblackP. NicolP. NyenweE. OdugbesanA.O. OkorochaY. Ortiz CarrasquilloR. OseiK. PalermoC. PatelH. PatelK. PauC. PerleyM. PlevinS. PlummerE. PowellR. QintarM. RawlsR. Reyes-CastanoJ. ReynoldsL. RichardsR. RosenstockJ. RoweC. SalehJ. SamS. SanchezA. SanderD. SandersonB. SavinV. SeaquistE. ShahJ. ShiS. ShivaswamyV. ShlotzhauerT. ShoreD. SkukowskiB. SoeK. SolheimV. SouferJ. SteinbergH. SteinsapirJ. TarkingtonP. ThayerD. ThomsonS. ThrasherJ. TibaldiJ. TjadenJ. ToresO. TrenceD. TrikudanathanS. UllalJ. UwaifoG. VoA. VuK. WaliaD. WeilandK. WhitehouseF. WiegmannT. WyneK. WynneA. YuenK. ZaretzkyJ. ZebrackJ. ZieveF. ZigrangW. REWIND Investigators Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.Lancet20193941019313113810.1016/S0140‑6736(19)31150‑X31189509
     [Google Scholar]
  150. MannJ.F.E. ØrstedD.D. Brown-FrandsenK. MarsoS.P. PoulterN.R. RasmussenS. TornøeK. ZinmanB. BuseJ.B. LEADER Steering Committee and Investigators Liraglutide and renal outcomes in type 2 diabetes.N. Engl. J. Med.2017377983984810.1056/NEJMoa161601128854085
     [Google Scholar]
  151. PerssonF. BainS.C. MosenzonO. HeerspinkH.J.L. MannJ.F.E. PratleyR. RazI. IdornT. RasmussenS. von ScholtenB.J. RossingP. LEADER Trial Investigators Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: A post hoc analysis of the LEADER trial.Diabetes Care20214441020102610.2337/dc20‑162233504496
     [Google Scholar]
  152. MannJ.F.E. HansenT. IdornT. LeiterL.A. MarsoS.P. RossingP. SeufertJ. TadayonS. VilsbøllT. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials.Lancet Diabetes Endocrinol.202081188089310.1016/S2213‑8587(20)30313‑232971040
     [Google Scholar]
  153. HeerspinkH.J.L. ApperlooE. DaviesM. DickerD. KandlerK. RosenstockJ. SørrigR. LawsonJ. ZeuthenN. CherneyD. Effects of semaglutide on albuminuria and kidney function in people with overweight or obesity with or without type 2 diabetes: Exploratory analysis from the STEP 1, 2, and 3 trials.Diabetes Care202346480181010.2337/dc22‑188936801984
     [Google Scholar]
  154. LincoffA.M. Brown-FrandsenK. ColhounH.M. DeanfieldJ. EmersonS.S. EsbjergS. Hardt-LindbergS. HovinghG.K. KahnS.E. KushnerR.F. LingvayI. OralT.K. MichelsenM.M. PlutzkyJ. TornøeC.W. RyanD.H. SELECT Trial Investigators Semaglutide and cardiovascular outcomes in obesity without diabetes.N. Engl. J. Med.2023389242221223210.1056/NEJMoa230756337952131
     [Google Scholar]
  155. ColhounH.M. LingvayI BrownP.M. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.Nat Med.20243072058206610.1038/s41591‑024‑03015‑5
     [Google Scholar]
  156. HeerspinkH. TuttleK. PavoI. HauptA. YangZ. WieseR. HemmingwayA. CherneyD. SattarN. LonguetC. Tirzepatide reduces albuminuria in patients with type 2 diabetes: Post hoc pooled analysis of surpass-1 to -5.Can. J. Cardiol.20233910S14410.1016/j.cjca.2023.06.231
     [Google Scholar]
  157. MahfoudF. CremersB. JankerJ. LinkB. VonendO. UkenaC. LinzD. SchmiederR. RumpL.C. KindermannI. SobotkaP.A. KrumH. SchellerB. SchlaichM. LaufsU. BöhmM. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension.Hypertension201260241942410.1161/HYPERTENSIONAHA.112.19387022733462
     [Google Scholar]
  158. OttC. MahfoudF. SchmidA. DittingT. VeelkenR. EwenS. UkenaC. UderM. BöhmM. SchmiederR.E. Improvement of albuminuria after renal denervation.Int. J. Cardiol.2014173231131510.1016/j.ijcard.2014.03.01724681017
     [Google Scholar]
  159. ZhangZ.H. YangK. JiangF.L. ZengL.X. JiangW.H. WangX.Y. The effects of catheter-based radiofrequency renal denervation on renal function and renal artery structure in patients with resistant hypertension.J. Clin. Hypertens. (Greenwich)201416859960510.1111/jch.1236725039997
     [Google Scholar]
  160. KiuchiM.G. GracianoM.L. CarreiraM.A.M.Q. KiuchiT. ChenS. LugonJ.R. Long-Term Effects of Renal Sympathetic Denervation on Hypertensive Patients With Mild to Moderate Chronic Kidney Disease.J. Clin. Hypertens. (Greenwich)201618319019610.1111/jch.1272426718019
     [Google Scholar]
  161. VerloopW.L. VinkE.E. SpieringW. BlankestijnP.J. DoevendansP.A. BotsM.L. VonkenE. VoskuilM. LeinerT. Effects of renal denervation on end organ damage in hypertensive patients.Eur. J. Prev. Cardiol.201522555856710.1177/204748731455600325326543
     [Google Scholar]
  162. PrasadB. BerryW. GoyalK. DehghaniP. TownsendR.R. Central blood pressure and pulse wave velocity changes post renal denervation in patients with stages 3 and 4 chronic kidney disease: The regina RDN study.Can. J. Kidney Health Dis.20196205435811982838810.1177/205435811982838830792873
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673348953250310044927
Loading
Microalbuminuria as a Prognostic Marker in Essential Hypertension
Curr. Med. Chem. 32, 8855 (2025); https://doi.org/10.2174/0109298673348953250310044927
/content/journals/cmc/10.2174/0109298673348953250310044927
/content/journals/cmc/10.2174/0109298673348953250310044927
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): endothelium; Hypertension; kidney; microalbuminuria; pharmacotherapy; predictive medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test